Trials explorer

AI-generated summary

- The ZANGEA trial tests zanidatamab together with pembrolizumab and chemotherapy in adults with metastatic gastroesophageal adenocarcinoma that is HER2-positive and PD-L1-positive, and who have not had palliative treatment before. - It is an open-label, single-arm phase II study enrolling about 80 patients at roughly 30 sites in Germany and Austria to assess efficacy, safety, tolerability, and quality of life. - The study also includes exploratory aims to compare results with a historical regimen and to identify molecular biomarkers that predict response or toxicity. - Key exclusions include untreated CNS metastases, active autoimmune disease, prior anti-HER2 therapy for GEA, certain infections, and pregnancy or breastfeeding.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

HER2-PET as a Precision Imaging Tool for Treatment With HER2-ADC in HER2-expressing mBC is being studied. Conditions: Breast Cancer Stage IV, HER2-low Breast Cancer, Molecular Imaging • Eligibility: Inclusion Criteria: * Female patients age ≥18 years. * Metastatic or locally advanced breast cancer with disease progression after ≥ 1 line of chemotherapy in the palliative setting,…. Goal: This is a prospective, multi-center, open-label, exploratory diagnostic phase II imaging trial for patients with metastatic breast cancer with at least one line of systemic therapy. The overarching aim of the HER2-Ex PET trial is to study the role of precision imaging utilizing positron emission tomography (PET) with the HER2-specific tracer \[68Ga\]Ga-ABY-025 (hereafter referred to as HER2-PET) in enhancing treatment planning for patients with metastatic HER2-expressing breast cancer Patients will be allocated based on HER2-status on PET and biopsy. Phase/Status/Sponsor: Unknown phase; RECRUITING; Renske Altena.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Real-world Effectiveness and Safety of Trastuzumab Deruxtecan in Patients With Locally Advanced or Metastatic HER2-positive Gastric or Gastroesophageal Junction Adenocarcinoma in China is being studied. Conditions: HER2-positive Gastric Cancer, HER2-positive Gastroesophageal Junction • Eligibility: Participants must meet all the following inclusion criteria to be eligible for the study: 1. Participants with pathologically diagnosed locally advanced unresectable or metastatic gastric cancer/gastroesophageal junction adenocarcinoma…. Goal: Trastuzumab deruxtecan's (T-DXd's) efficacy and safety has been confirmed in traditional clinical trials, there is a lack of real-world evidence, especially among Chinese patients. The objective of this study is to evaluate real-world effectiveness and safety profile of T-DXd by collecting real-world data treating in patients with locally advanced or metastatic HER2-positive gastric or gastroesophageal junction adenocarcinoma. Phase/Status/Sponsor: Unknown phase; RECRUITING; Daiichi Sankyo.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

This trial tests a new PET/CT tracer, 68GaNOTA-Anti-HER2 VHH1, to image HER2 expression in tumors. It is for adults with locally advanced or metastatic breast cancer (cohort 1), other HER2-expressing cancers (cohort 2), and HER2-positive breast cancer planned for neoadjuvant treatment (cohort 3), and the study is currently recruiting. The goal is to learn how repeatable the HER2 imaging is and how tracer uptake matches biopsy results when available, plus whether the tracer adds value in the neoadjuvant setting. Key exclusions include pregnancy or breastfeeding, serious infections or other life-threatening illnesses, inability to consent or cooperate, and, for cohorts 1 and 3, prior participation in this study.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Study of T-DXd for the Treatment of Solid Tumors Harboring HER2 Activating Mutations is being studied. Conditions: Advanced Solid Tumors With HER2 Mutation,eg:Colorectal,Urothelial,Gastric, Hepatobiliary,Endometrial,Melanoma,Ovarian,Cervical,Salivary Gland,Pancreatic,Breast • Eligibility: Inclusion Criteria: * Adults ≥18 years old. Other age restrictions may apply as per local regulations. * Unresectable and/or metastatic solid tumors with pre-specified HER2 mutations (S310F, S310Y,…. Goal: This is an open-label, multi-center, single arm, Phase II study to evaluate the efficacy and safety of T-DXd for the treatment of unresectable and/or metastatic solid tumors harboring specific HER2 activating mutations regardless of tumor histology. The target population are patients who have progressed following prior treatment or who have no satisfactory alternative treatment options, including approved second line therapies in the specific tumor type. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; AstraZeneca.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

This open, multicenter trial tests SHR-A1811 combined with chemotherapy and/or immunotherapy in adults with HER2-positive advanced or metastatic gastric or gastroesophageal junction cancer. It has two parts: Phase Ib to assess safety, tolerability, how the drug behaves in the body, immune response, and early anti-tumor signals; Phase II to assess how well the combination works and its safety. Eligible participants are adults aged 18 to 75 with unresectable or metastatic HER2-positive gastric/GEJ adenocarcinoma; Phase Ib includes people who have had prior therapy or none, while Phase II is for previously untreated patients. Key exclusions include symptomatic ascites or effusions needing treatment, active autoimmune disease or interstitial pneumonia, severe infection, recent major surgery, active tuberculosis in the past year, and serious cardiovascular or cerebrovascular disease. The trial is currently recruiting.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Diagnostic HER2DX-guided Treatment for Patients wIth Early-stage HER2-positive Breast Cancer is being studied. Conditions: HER2-positive Breast Cancer, Early-stage Breast Cancer • Eligibility: Inclusion Criteria: 1. Signed informed consent must be obtained prior to any trial-specific procedure. Note: Candidate patients in France must be affiliated to a Social Security System (or…. Goal: The primary goal of the DEFINITIVE trial is to demonstrate the effectiveness of the HER2DX diagnostic assay in enhancing the management of patients with early-stage HER2- positive breast cancer. Patients randomized to arm A will receive adjuvant treatment by physician´s choice, blinded to the diagnostic HER2DX test results. Phase/Status/Sponsor: Unknown phase; RECRUITING; Fundacio Clinic Barcelona.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Pilot Study of Neoadjuvant Chemotherapy Combined With Immunotherapy and Multimodal Thermal Therapy for HER2-negative Breast Cancer is being studied. Conditions: Breast Cancer Female, HER2-negative Breast Cancer • Eligibility: Inclusion Criteria: 1. Female，age 18-70 years. 2. Histologically confirmed invasive cancer of the breast, and patients meeting cT2-4N+M0 criteria; 3. TNBC non-immunoregulation subtype or HR+/HER2- status were measured…. Goal: In this study, breast cancer (BC) patients eligible for inclusion will be divided into two groups according to molecular typing and subtyping, which combined immunotherapy and multimodal thermal therapy with conventional neoadjuvant chemotherapy, to explore methods of immune induction for BC, enhance the efficacy of immunotherapy, and accumulate data for subsequent stages of clinical study. Phase/Status/Sponsor: Unknown phase; RECRUITING; Fudan University.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Copper Cu 64-DOTA-Trastuzumab PET in Predicting Response to Treatment With Ado-Trastuzumab Emtansine in Patients With Metastatic HER2 Positive Breast Cancer is being studied. Conditions: Bone Metastases, HER2-positive Breast Cancer, Liver Metastases +4 • Eligibility: Inclusion Criteria: * Participants must be women who have histological confirmation of metastatic invasive breast cancer that has metastasized outside the region of the primary tumor and axilla;…. Goal: This pilot clinical trial studies how well copper Cu 64-tetra-azacyclododecanetetra-acetic acid (DOTA)-trastuzumab positron emission tomography (PET) works in predicting response to treatment with ado-trastuzumab emtansine in patients with human epidermal growth factor receptor 2 (HER2) positive breast cancer that has spread to other places in the body. Copper Cu 64-DOTA-trastuzumab is a chemotherapy drug (trastuzumab) attached to a radioactive substance. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; City of Hope Medical Center.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

This trial tests ZW25 (zanidatamab) added to standard first-line chemotherapy in people with HER2-expressing gastrointestinal cancers that are unresectable or metastatic, specifically gastroesophageal adenocarcinoma, biliary tract cancer, or colorectal cancer. The study has two parts: Part 1 checks safety and tolerability and helps establish a recommended dose for the combination, and Part 2 evaluates the anti-tumor activity. Eligible participants have HER2-expressing tumors, are unresectable or metastatic, and have good performance status with adequate organ and heart function; colorectal cancer participants must have wild-type RAS/BRAF, with additional biomarker criteria by part. Key exclusions include prior HER2-targeted therapy, recent systemic cancer treatment (with limited exceptions), untreated brain metastases, significant cardiac disease, QTc prolongation, active infections, or uncontrolled HIV/HBV/HCV.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Binary Oncolytic Adenovirus in Combination With HER2-Specific Autologous CAR VST, Advanced HER2 Positive Solid Tumors is being studied. Conditions: Bladder Cancer, Head and Neck Squamous Cell Carcinoma, Cancer of the Salivary Gland +7 • Eligibility: Inclusion Criteria: This study will look at solid tumors (as a basket trial for any solid cancer) with HER2 positivity based on IHC Procurement Inclusion Criteria 1. The…. Goal: This study is a first in human Phase 1 study that involves patients with a type of cancer called HER2 (Human Epidermal Growth Factor Receptor 2) positive cancer. This study asks patients to volunteer to take part in a research study investigating the safety and efficacy of using special immune cells called HER2 chimeric antigen receptor specific cytotoxic T lymphocytes (HER2 specific CAR T cells), in combination with intra-tumor injection of CAdVEC, an oncolytic adenovirus that is designed to help the immune system including HER2 specific CAR T cell react to the tumor. Phase/Status/Sponsor: Unknown phase; RECRUITING; Baylor College of Medicine.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

HER2 Molecular Imaging With 89Zr-trastuzumab PET/CT as a Predictive Biomarker for Antibody-drug Conjugate Sequencing in Patients With Advanced HER2-positive Breast Cancer is being studied. Conditions: HER2-positive Metastatic Breast Cancer, HER2-positive Advanced Breast Cancer • Eligibility: Inclusion Criteria: * ECOG performance status ≤ 1 * Must have histologically or cytologically confirmed progressive advanced/metastatic HER2-positive breast carcinoma as per the updated American Society of Clinical…. Goal: ZEPHIR-02 is a multicentre, open-label phase II study that will enroll subjects with HER2-positive advanced/metastatic breast cancer (mBC) who have experienced disease progression under trastuzumab deruxtecan (T-DXd) in the metastatic setting. All subjects will undergo baseline biopsy, blood collection, FDG-PET/CT and 89Zr-trastuzumab PET/CT (HER2-PET/CT) and will be classified as HER2-PET/CT positive or negative, as previously described in the ZEPHIR trial. Phase/Status/Sponsor: Unknown phase; NOT_YET_RECRUITING; Jules Bordet Institute.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Clinical Study of SPH5030 Tablets in the Treatment of Her2-positive/Mutated Biliary Tract OR Colorectal Cancer Patients. is being studied. Conditions: Biliary Tract or Colorectal Cancer With Her2-positive/Mutated • Eligibility: Inclusion Criteria: 1. Metastatic and/or unresectable advanced colorectal adenocarcinoma, or locally advanced, recurrent, metastatic and/or unresectable advanced biliary tract carcinoma 2. HER2 positive or HER2 gene mutation; 3.…. Goal: To evaluate the efficacy and safety of SPH5030 tablets in subjects with Her2-positive/mutated biliary tract OR colorectal cancer. Phase/Status/Sponsor: Unknown phase; RECRUITING; Shanghai Pharmaceuticals Holding Co., Ltd.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Dose Finding Study of ZW49 in Patients With HER2-Positive Cancers is being studied. Conditions: HER2-expressing Cancers • Eligibility: Inclusion Criteria: * Pathologically-confirmed diagnosis of breast cancer, gastroesophageal adenocarcinoma (GEA), or other HER2-expressing cancer with evidence of locally advanced (unresectable) and/or metastatic disease. * Dose-escalation (Cohort 1):…. Goal: This is a first-in-human, Phase 1, multicenter, open-label, dose-escalation study to establish the maximum-tolerated dose (MTD) or recommended dosage (RD) of ZW49, the investigational agent under study, and to assess the safety and tolerability of ZW49. Eligible patients include those with locally advanced (unresectable) or metastatic HER2-expressing cancers. Phase/Status/Sponsor: Unknown phase; COMPLETED; Zymeworks BC Inc..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Study Evaluating the Efficacy and Safety of Giredestrant Compared With Physician's Choice of Endocrine Monotherapy in Participants With Previously Treated Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer (acelERA Breast Cancer) is being studied. Conditions: Estrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer • Eligibility: Inclusion Criteria: * Women who are postmenopausal or premenopausal/perimenopausal * For women who are premenopausal or perimenopausal and for men: willing to undergo and maintain treatment with approved…. Goal: This Phase II, randomized, open-label, multicenter study will evaluate the efficacy and safety of giredestrant compared with physician's choice of endocrine monotherapy in participants with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer who have received one or two prior lines of systemic therapy in the locally advanced or metastatic setting. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; Hoffmann-La Roche.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2 is being studied. Conditions: Urothelial Carcinoma • Eligibility: Inclusion Criteria: Cohorts A and B * Histopathologically-confirmed, locally-advanced, unresectable or metastatic urothelial cancer (LA/mUC), including UC originating from the renal pelvis, ureters, bladder, or urethra * Participants…. Goal: This study is being done to see if a drug called disitamab vedotin, alone or with pembrolizumab, works to treat HER2 expressing urothelial cancer. It will also test how safe the drug is for participants. Phase/Status/Sponsor: Unknown phase; RECRUITING; Seagen, a wholly owned subsidiary of Pfizer.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Clinical Trial Evaluating the Activity of Zanidatamab for the Treatment of Patients With Solid Tumors With an Alteration of the HER2 Gene. is being studied. Conditions: Non-Small Cell Lung Cancer, Sarcoma, Head &Amp; Neck Cancer +2 • Eligibility: Inclusion Criteria: 1. Histologically or cytologically confirmed endometrial, colorectal, head \& neck, non-small cell lung cancer (NSCLC), or sarcoma 2. Patient with progressive, unresectable and/or advanced or metastatic…. Goal: Alterations in the HER2 gene are involved in the development of cancer. These abnormalities are found at highly variable rates (from approximately 2% to 60%) in cancers of the lung, breast, stomach, bile ducts, salivary glands, colon, endometrium, uterus, bladder, bones, blood, etc. Phase/Status/Sponsor: Unknown phase; RECRUITING; UNICANCER.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

[177Lu]Lu-NeoB in Combination With Ribociclib and Fulvestrant in Participants With ER+, HER2- and GRPR+ Advanced Breast Cancer is being studied. Conditions: Breast Cancer • Eligibility: Key Inclusion criteria: * Adult female or male \>= 18 years of age at the time of informed consent * Histologically and/or cytologically confirmed diagnosis of estrogen-receptor positive…. Goal: The purpose of this trial is to estimate the recommended dose (RD) of \[177Lu\]Lu-NeoB in combination with ribociclib and fulvestrant in participants with estrogen receptor (ER) positive (ER+), human epidermal growth factor receptor-2 (HER2) negative (HER2-) and gastrin releasing peptide receptor (GRPR) positive (GRPR+) advanced breast cancer experiencing early relapse from (neo)adjuvant endocrine therapy or who have progressed on endocrine therapy in combination with a CDK4/6 inhibitor for advanced disease. Phase/Status/Sponsor: Unknown phase; RECRUITING; Novartis Pharmaceuticals.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Randomized Controlled Clinical Study of Efficacy and Safety of Initumab Combined with Pyrrotinib and Chemotherapeutic Agents in Neoadjuvant Therapy for HER2-positive Breast Cancer with Different Treatment Cycles is being studied. Conditions: HER2 Positive Breast Cancer • Eligibility: inclusion criteria： 1\. Age ≥18 years old, while ≤70 years old, gender is not limited; 2.2. Invasive breast cancer confirmed histologically by air-core needle biopsy; According to AJCC…. Goal: The purpose of this study was to explore the efficacy and safety of initumab combined with pyrrotinib and chemotherapy for 4 cycles and 6 cycles of neoadjuvant therapy for HER2-positive breast cancer, and to explore the efficacy and safety of continued use of initumab combined with pyrrotinib in pCR patients. This study adopted A prospective, randomized controlled, open-label design, and selected eligible subjects to be randomly divided into cohort A and Cohort B. Phase/Status/Sponsor: Unknown phase; NOT_YET_RECRUITING; The First Hospital of Jilin University.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Basket Study of Neratinib in Participants With Solid Tumors Harboring Somatic HER2 or EGFR Exon 18 Mutations is being studied. Conditions: Solid Tumors Harboring Somatic HER2 or EGFR Exon 18 Mutations • Eligibility: Inclusion Criteria: * Provide written informed consent * Histologically confirmed cancers for which no curative therapy exists * Documented HER2 or EGFR exon 18 mutation * Participants must…. Goal: This is an open-label, multicenter, multinational, Phase 2 basket study exploring the efficacy and safety of neratinib as monotherapy or in combination with other therapies in participants with HER (EGFR, HER2) mutation-positive solid tumors. Phase/Status/Sponsor: Unknown phase; TERMINATED; Puma Biotechnology, Inc..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Real-World Study in Patients With HR+/HER2- Advanced Breast Cancer is being studied. Conditions: Breast Cancer Metastatic, HR+/HER2- Advanced Breast Cancer • Eligibility: Inclusion Criteria: * 1\. must have a histologically or cytologically confirmed diagnosis of breast cancer and evidence of locally advanced or metastatic disease that is not amenable to…. Goal: The goal of this observational study is to learn about the safety and effectiveness of people with advanced breast cancer that is hormone receptor-positive (HR+), HER2-negative (HER2-). Participants will: Allow researchers to collect medical data during routine care Be followed for signs of treatment effectiveness and any medical problems that happen while taking the drug Phase/Status/Sponsor: Unknown phase; WITHDRAWN; SciClone Pharmaceuticals.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Phase I Study of Autologous Tumor-Draining Lymph Node-Derived Lymphocytes for Advanced HER2-Negative Breast Cancer is being studied. Conditions: Breast Neoplasms • Eligibility: Inclusion Criteria: In order to be eligible for participation in this trial, the participant must: 1. Have signed the informed consent to study participation. 2. Be a female…. Goal: RATIONALE: Patients with HER2-negative advanced breast cancer have limited choice on targeted therapies, and often show only modest responses to available immunotherapies. Adoptive cell therapy with tumor-infiltrating lymphocytes has difficulties in preparing enough cells from solid tumors and overcoming the exhaustion and dysfunction of T cells, which limit its clinical use. Phase/Status/Sponsor: Unknown phase; RECRUITING; Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Clinical Trial Evaluating the Biological Activity of a New Drug Identified as Prifetrastat (PF-07248144), Combined With Fulvestrant for the Treatment of Patients With Hormone Receptor Positive (HR+) and HER2 Negative (HER2-) Breast Cancer Extended to Other Organs. is being studied. Conditions: Metastatic (Stage IV) Melanoma • Eligibility: Inclusion Criteria: In order to participate in the trial, all patients must meet all the following criteria: 1. Patient must have signed the written informed consent prior to…. Goal: Although treatments for breast cancer have improved, 20-30% of patients with early disease develop metastases (cancer that spreads to other parts of the body). Among the different types of breast cancer, hormone-sensitive cancers that do not overexpress the HER2 protein (HR+/HER2-) are the most common. Phase/Status/Sponsor: Unknown phase; NOT_YET_RECRUITING; UNICANCER.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Phase 1b/2 Study of T-DXd Combinations in HER2-positive Metastatic Breast Cancer is being studied. Conditions: Metastatic Breast Cancer • Eligibility: Key Inclusion Criteria: * Patients must be at least 18 years of age * Pathologically documented breast cancer that: 1. Is advanced/unresectable (patients that can be treated with…. Goal: DESTINY-Breast07 will investigate the safety, tolerability, and anti-tumour activity of trastuzumab deruxtecan (T-DXd) in combination with other anti-cancer agents in patients with HER2-positive Metastatic Breast Cancer Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; AstraZeneca.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Clinical Trail of KJ015 in Patients With HER2-Expressing Solid Tumors is being studied. Conditions: Gastric/Gastroesophageal Junction Cancer, Breast Cancer, Colorectal Cancer +3 • Eligibility: Inclusion Criteria: 1. Aged ≥ 18 years (at time of free and informed consent). 2. Participants must have radiographically confirmed progressive disease (PD) during the last treatment prior…. Goal: This is an open-label, multicenter, Phase 1 study to evaluate the safety, tolerability, PK, and preliminary efficacy of KJ015 administered subcutaneously in participants with HER2-expressing solid tumors. Phase/Status/Sponsor: Unknown phase; NOT_YET_RECRUITING; Shanghai Bao Pharmaceuticals Co., Ltd..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Exploratory Study of Advanced Breast Cancer in HER2 Positive Patients With Failure of Multi-line Therapy Treated by Combination of Inetetamab (Cipterbin) + PD-1 Inhibitor Combined With Utidelone. is being studied. Conditions: HER2 Positive Metastatic Breast Cancer • Eligibility: Inclusion Criteria: 1. Age: 18-75 years old female patients; 2. The results showed that HER-2 was positive at least once in patients with recurrent and metastatic breast cancer…. Goal: This study plans to explore the efficacy and safety of chemotherapy combined with inetetamab and PD-1 inhibitors in HER2 positive advanced breast cancer who failed to receive trastuzumab and TKIs, and explore the dominant population of dual antibody combination to further guide the precise and individualized treatment of advanced HER2 positive breast cancer. Phase/Status/Sponsor: Unknown phase; UNKNOWN; Henan Cancer Hospital.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy for Advanced HER2-positive Biliary Tract Cancer is being studied. Conditions: Biliary Tract Cancer • Eligibility: Inclusion Criteria 1. Histologically- or cytologically-confirmed Biliary Tract Cancer (BTC), including Gallbladder Cancer (GBC), Intrahepatic Cholangiocarcinoma (ICC), or Extrahepatic Cholangiocarcinoma (ECC). 2. Locally advanced unresectable or metastatic BTC…. Goal: The purpose of this study is to evaluate the efficacy and safety of Zanidatamab plus CisGem (Cisplatin and Gemcitabine) with or without the addition of a programmed death protein 1/ligand-1 (PD-1/L1) inhibitor (physician's choice of either Durvalumab or Pembrolizumab, where approved under local regulations) as first line of treatment for participants with human epidermal growth factor receptor 2 (HER2)-positive biliary tract cancer. Phase/Status/Sponsor: Unknown phase; RECRUITING; Jazz Pharmaceuticals.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

ECLECTIC: EstroTEP and Circulating Biomarkers for ER-positive HER2-negative Metastatic Breast Cancer Patients is being studied. Conditions: Breast Carcinoma • Eligibility: Inclusion Criteria: 1. Metastatic invasive breast carcinoma of no special type. 2. Females and males of age ≥18 years. 3. Life expectancy \> 3 months. 4. Eastern Cooperative…. Goal: Eclectic is a strategy trial; once the class of treatment (endocrine therapy or chemotherapy) has been allocated according to 16α-18F-fluoro-17β-oestradiol (18F-FES) Positron Emission Tomography/Computed Tomography (PET/CT) results and circulating tumor biomarkers, clinicians will decide which treatment to use. Phase/Status/Sponsor: Unknown phase; RECRUITING; Institut Curie.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Study of Palbociclib in Addition to Standard Endocrine Treatment in Hormone Receptor Positive Her2 Normal Patients With Residual Disease After Neoadjuvant Chemotherapy and Surgery is being studied. Conditions: Breast Cancer, Hormonreceptor Positive, Her2-normal +2 • Eligibility: Based on protocol G version 11 dated 09 April 2019 Inclusion Criteria 1. Written informed consent prior to beginning specific protocol procedures, including expected cooperation of the patients…. Goal: The PENELOPEB study is designed to demonstrate that, in the background of standard anti-hormonal therapy, palbociclib provides superior invasive disease-free survival (iDFS) compared to placebo in pre- and postmenopausal women with HR-positive/HER2-normal early breast cancer at high risk of relapse after showing less than pathological complete response to neoadjuvant taxane- containing chemotherapy. Considering the high risk of recurrence in patients after neoadjuvant chemotherapy and a high CPS-EG score, palbociclib appears to be an attractive option with a favourable safety profile for these patients. Phase/Status/Sponsor: Unknown phase; COMPLETED; GBG Forschungs GmbH.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene is being studied. Conditions: HER2-positive Breast Cancer, HER2 Gene Mutation, HER-2 Gene Amplification +41 • Eligibility: Inclusion Criteria: Phase I Patients must meet the following criteria for inclusion into the study: 1. Patients must be able to provide documented voluntary informed consent. 2. Male…. Goal: Open-label, Phase I-II, first-in-human (FIH) study for A166 monotherapy in HER2-expressing or amplified patients who progressed on or did not respond to available standard therapies. Patients must have documented HER2 expression or amplification. Phase/Status/Sponsor: Unknown phase; COMPLETED; Klus Pharma Inc..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Study of Disitamab Vedotin Combined With Trastuzumab and Tislelizumab Versus Chemotherapy Combined With Trastuzumab With or Without Pembrolizumab in HER2-high Expression Advanced Gastric or Gastroesophageal Junction Adenocarcinoma. is being studied. Conditions: Gastric Carcinoma • Eligibility: Inclusion Criteria: * Voluntarily consent to participate in the study and sign the informed consent form * Expected survival period \>12 weeks * ECOG Performance Status 0 or…. Goal: The purpose of this study is to evaluate the efficacy and safety of Disitamab Vedotin combined with Trastuzumab and Tislelizumab Versus Chemotherapy Combined with Trastuzumab with or without Pembrolizumab as First-Line Treatment for Advanced Gastric/Gastroesophageal Junction Adenocarcinoma with HER2-high Expression. Phase/Status/Sponsor: Unknown phase; RECRUITING; RemeGen Co., Ltd..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

ACE1702 in Subjects With Advanced or Metastatic HER2-expressing Solid Tumors is being studied. Conditions: Locally Advanced Solid Tumor, Metastatic Cancer, Solid Tumor +2 • Eligibility: Inclusion Criteria: * Signed informed consent * Subjects must be ≥ 18 years of age ( ≥ 20 years of age for Taiwan site) * Subject with advanced…. Goal: ACE1702 (anti-HER2 oNK cells) is an off-the-shelf Natural Killer (NK) cell product that targets human HER2-expressing solid tumors. The ACE1702-001 phase I study aims to evaluate the safety and tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of ACE1702 in patients with advanced or metastatic HER2-expressing tumors, and to determine the phase Ib/II starting dose for ACE1702. Phase/Status/Sponsor: Unknown phase; COMPLETED; Acepodia Biotech, Inc..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Study of Sigvotatug Vedotin in Advanced Solid Tumors is being studied. Conditions: Carcinoma, Non-Small Cell Lung, Squamous Cell Carcinoma of Head and Neck, HER2 Negative Breast Neoplasms +9 • Eligibility: Inclusion Criteria: * Disease indication * Participants must have histologically or cytologically confirmed metastatic or unresectable solid malignancy within one of the tumor types listed below (dependent on…. Goal: This trial will look at a drug called sigvotatug vedotin (SGN-B6A) alone and with pembrolizumab, with or without chemotherapy, to find out whether it is safe for people who have solid tumors. It will study sigvotatug vedotin to find out what its side effects are. Phase/Status/Sponsor: Unknown phase; RECRUITING; Seagen, a wholly owned subsidiary of Pfizer.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Study to Evaluate Patient Preference and Satisfaction of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Participants With HER2-Positive Early Breast Cancer is being studied. Conditions: HER2-Positive Early Breast Cancer • Eligibility: Inclusion Criteria: Disease-specific criteria: * Female or male with histologically confirmed, HER2-positive (HER2+) inflammatory, locally advanced or early-stage breast cancer who have received neoadjuvant pertuzumab and trastuzumab and…. Goal: This is a Phase II, randomized, multicentre, multinational, open-label, cross-over study in adult patients who have completed neoadjuvant chemotherapy with neoadjuvant pertuzumab and trastuzumab and have undergone surgical treatment of human epidermal growth factor receptor 2 (HER2)-positive early breast cancer. The study will consist of two adjuvant treatment periods: a treatment cross-over period and a treatment continuation period. Phase/Status/Sponsor: Unknown phase; COMPLETED; Hoffmann-La Roche.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Stereotactic Radiation Therapy for HE2-positive Oligometastatic Breast Cancer is being studied. Conditions: HER2-positive Metastatic Breast Cancer, Oligometastatic Disease • Eligibility: Inclusion Criteria: 1. Patients must be at least 18 years of age and able to give written informed consent and comply with study procedures; 2. Clinical diagnosis: breast…. Goal: This study involves two non-randomized groups of patients: the observation group and the comparison group. The comparison group will retrospectively include data on 29 patients with oligometastatic HER2-positive breast cancer who received treatment with trastuzumab-emtansine and had a history of SRT. Phase/Status/Sponsor: Unknown phase; RECRUITING; N.N. Petrov National Medical Research Center of Oncology.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Study of Disitamab Vedotin and Anlotinib in Patients With HR-Negative, HER2-Low-Expressing Metastatic Breast Cancer is being studied. Conditions: Breast Cancer • Eligibility: Inclusion Criteria: * 1)At the time of signing the informed consent form, the age is ≥ 18 years old, regardless of gender; * 2)Patients with pathohistologically proven, locally…. Goal: Disitamab Vedotin (RC48) contains the novel humanized anti-HER2 antibody conjugated to monomethyl auristatin E (MMAE) via a cleavable linker , which is the first ADC drug that was independently developed by Rongchang Biology .The aim of this study is to evaluate the efficacy and safety of RC48 in Combination with Anlotinib for the treatment of metastatic breast cancer with HR negativity and HER2 low expression. Phase/Status/Sponsor: Unknown phase; UNKNOWN; Qilu Hospital of Shandong University.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Iparomlimab and Tuvonralimab (QL1706) in Patients With HR-positive, HER2-negative Advanced Breast Cancer is being studied. Conditions: Advanced Breast Cancer • Eligibility: Inclusion Criteria: * Female, age≥18 years old * Expected survival ≥12 weeks * ECOG 0-1 * Pathologically confirmed recurrent or metastatic breast cancer not amenable to curative surgery…. Goal: This is a prospective, randomised, controlled, multicentre study to evaluate the efficacy and safety of Iparomlimab and Tuvonralimab (QL1706) in patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer. Phase/Status/Sponsor: Unknown phase; RECRUITING; Wenjin Yin.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Adjuvant Abemaciclib for Locoregional Recurrence of HR-positive, HER2-negative Breast Cancer (JCOG2313, AURA) is being studied. Conditions: Breast Cancer, Locoregional Recurrence, Abemaciclib +1 • Eligibility: Inclusion criteria: 1. The patient has been diagnosed with the first locoregional recurrence (LRR) after receiving definitive treatment for primary breast cancer. LRR includes one or more of…. Goal: The JCOG2313 trial is a multicenter, randomized, phase III study designed to evaluate the efficacy and safety of adjuvant abemaciclib in combination with endocrine therapy versus endocrine therapy alone in patients with hormone receptor (HR)-positive, HER2-negative breast cancer who have undergone curative treatment for their first locoregional recurrence (LRR). Although HR-positive, HER2-negative breast cancer generally has a favorable prognosis, LRR-such as ipsilateral breast tumor recurrence (IBTR), chest wall recurrence, or regional lymph node recurrence-remains a clinically significant event that increases the risk of distant metastasis. Phase/Status/Sponsor: Unknown phase; RECRUITING; Japanese Foundation for Cancer Research.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Study of BL-M17D1 in Patients With Locally Advanced or Metastatic HER2 Positive/Lower Expression Gastrointestinal Cancer and Other Solid Tumors is being studied. Conditions: Esophageal Cancer, Gastric Cancer, Pancreatic Cancer +2 • Eligibility: Inclusion Criteria: 1. Voluntarily sign the informed consent and follow the requirements of the protocol; 2. No gender limit; 3. Age: ≥18 years old and ≤75 years old…. Goal: This study is an open, multicenter, dose-escalation and expansion-enrollment nonrandomized phase I clinical study to evaluate the safety, tolerability, pharmacokinetic characteristics and preliminary efficacy of BL-M17D1 in locally advanced or metastatic HER2 positive/lower expression gastrointestinal cancer and other solid tumors. Phase/Status/Sponsor: Unknown phase; RECRUITING; Sichuan Baili Pharmaceutical Co., Ltd..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Phase II Basket Trial: Zanidatamab Plus Tislelizumab in HER2-Positive GI Tumors (UNION-HER2-BASKET) is being studied. Conditions: Locally Advanced Rectal Cancer (LARC), Locally Advanced Gastric/Gastroesophageal Junction Adenocarcinoma, Metastatic Colorectal Cancer (mCRC) +1 • Eligibility: Inclusion Criteria: * Clinical diagnosis of gastric cancer and colorectal cancer * Aged 18 to 75 years: * Able to sign a written informed consent form and understand…. Goal: This study is a prospective, multi-cohort clinical trial designed to evaluate the preliminary efficacy and safety of zanidatamab in combination with tislelizumab and chemotherapy/radiotherapy for patients with HER2-positive locally advanced or metastatic gastrointestinal tumors. Phase/Status/Sponsor: Unknown phase; NOT_YET_RECRUITING; Tao Zhang.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Study to Investigate the Prevalence of Human Epidermal Growth Factor Receptor 2 (HER2) Immunohistochemistry (IHC) 3+ and Characterize the Clinicopathologic Features of Gynecologic Cancers in Taiwan is being studied. Conditions: Cervical Cancers, Endometrial Cancer, Ovarian Cancer • Eligibility: Inclusion Criteria: 1. Adults aged ≥ 18 years when their clinical data are reviewed 2. Patients who fulfill ONE of the following criteria * Imaging or histological diagnosis…. Goal: Trastuzumab Deruxtecan (T-DXd) is a humanized anti-HER2 monoclonal antibody covalently linked to DXd, which is a topoisomerase 1 inhibitor. T-DXd has been approved for the treatment of HER2-positive breast cancer, HER2-mutated lung cancer, HER2-positive gastric cancer, and HER2-low breast cancer in Taiwan. Phase/Status/Sponsor: Unknown phase; COMPLETED; Daiichi Sankyo.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Study of SHR-A1811 in HER2-expression Advanced Breast Cancer with Brain Metastases is being studied. Conditions: Metastatic Breast Cancer • Eligibility: Inclusion Criteria: 1. Females ≥18 yrs old; 2. Pathologically confirmed HER2-positive or HER2-low advanced breast cancer; 3. At least one measurable intracranial lesion according to RANO-BM criteria, which…. Goal: This study aimed to evaluate the use of SHR-A1811 in HER2-expression Advanced Breast Cancer patients with brain metastases. Phase/Status/Sponsor: Unknown phase; RECRUITING; Henan Cancer Hospital.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Ribociclib for HR-positive HER2-negative Metastatic Breast Cancer is being studied. Conditions: Breast Cancer • Eligibility: Inclusion Criteria: * Histologically confirmed invasive breast cancer. * Hormone receptor-positive (ER positive and/or PgR positive) and HER2-negative disease: ER positive: ≥1% positive cells or Allred score ≥3.…. Goal: This document outlines an investigator-initiated Phase Ib/II clinical trial in Japan, focusing on the combination therapy of ribociclib and anastrozole for patients with hormone receptor-positive (HR-positive), HER2-negative metastatic or recurrent breast cancer. The trial aims to evaluate the efficacy (specifically, overall response rate) and safety of this combination in the Japanese patient population. Phase/Status/Sponsor: Unknown phase; NOT_YET_RECRUITING; Nagoya City University.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Neoadjuvant Endocrine Therapy in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Node-Negative Breast Cancer is being studied. Conditions: Breast Cancer, Invasive Breast Cancer • Eligibility: Inclusion Criteria: * Female; age ≥18 years. * Pathologically proven diagnosis of invasive breast cancer, clinically stage I-II. * Clinically lymph node negative, confirmed by clinical exam and/or…. Goal: This is an exploratory interventional study that initiates standard-of-care anti-estrogen treatment preoperatively for four weeks. Phase/Status/Sponsor: Unknown phase; COMPLETED; Medical College of Wisconsin.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Cohort Study on Sequential ADC Therapy in HR-positive/HER2-negative Advanced Breast Cancer is being studied. Conditions: Breast Neoplasms • Eligibility: Inclusion Criteria: 1. Adult patients ≥18 years old; 2. Histologically or cytologically confirmed HR+/HER2- (HER2 IHC 0/IHC 1+ or IHC 2+ with FISH-negative) locally advanced unresectable or metastatic…. Goal: The combination of cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) and endocrine therapy is the standard first-line treatment for advanced HR+ (hormone receptor-positive)/HER2- (human epidermal growth factor receptor 2-negative) breast cancer. However, the optimal treatment strategy after CDK4/6i progression remains unclear. Phase/Status/Sponsor: Unknown phase; NOT_YET_RECRUITING; Yan Xue.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Testing Afatinib as a Potential Targeted Treatment in Cancers With HER2 Genetic Changes (MATCH-Subprotocol B) is being studied. Conditions: Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Hematopoietic and Lymphoid Cell Neoplasm +3 • Eligibility: Inclusion Criteria: * Patients must have met applicable eligibility criteria in the Master MATCH Protocol prior to registration to treatment subprotocol * Patient's tumor must have activating HER2…. Goal: This phase II MATCH treatment trial identifies the effects of afatinib in patients whose cancer has genetic changes called HER2 mutations. Afatinib may stop the growth of cancer cells by blocking the HER2 receptor, a protein that may be needed for cell growth. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; National Cancer Institute (NCI).

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

The AVIATOR Study: Trastuzumab and Vinorelbine With Avelumab OR Avelumab & Utomilumab in Advanced HER2+ Breast Cancer is being studied. Conditions: Breast Cancer • Eligibility: Inclusion Criteria: * Age ≥18 years or older * Histologically confirmed breast adenocarcinoma that is unresectable loco-regionally advanced or metastatic * HER2-positive (immunohistochemistry score 3+) or ERBB2- amplification…. Goal: This research study is studying a combination of drugs as a possible treatment for breast cancer. The drugs involved in this study are: * Group A: Trastuzumab (Herceptin) + Vinorelbine (Navelbine) * Group B: Trastuzumab + Vinorelbine + Avelumab * Group C: Trastuzumab + Vinorelbine + Avelumab + Utomilumab (PF-05082566) Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; Adrienne G. Waks.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

This is an open-label, single-arm phase II trial testing perioperative therapy that combines pembrolizumab, trastuzumab, and FLOT before surgery, then pembrolizumab plus trastuzumab after surgery for up to one year. It is for adults with HER2-positive localized esophagogastric adenocarcinoma that is potentially curable by surgery and has no distant metastasis. The study mainly aims to see if this treatment improves disease-free survival and increases the rate of pathological complete response (pCR) after surgery, compared with historical outcomes. Eligibility excludes metastatic disease, prior anti-PD-1/PD-L1 therapy, major heart problems, active infections or autoimmune disease, pregnancy, or other serious health risks.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Study to Compare Neoadjuvant Combination of Trastuzumab and Pertuzumab With Concurrent Taxane Chemotherapy or Endocrine Therapy and Quality of Life Assessment Under Adjuvant Therapy in Operable HER2+/HR+ Breast Cancer Patients is being studied. Conditions: Breast Neoplasms • Eligibility: Inclusion Criteria: * Female patients, age at diagnosis 18 years and older * Histologically confirmed unilateral primary invasive carcinoma of the breast * Patients must qualify for neoadjuvant…. Goal: This is a prospective, phase IIa, multicenter, randomized, open-label study comparing a pre-surgical combination of trastuzumab and pertuzumab with concurrent weekly paclitaxel chemotherapy or endocrine therapy given for 12 weeks with a quality of life assessment for 40 additional weeks in patients with operable HER2+/HR+ breast cancer. Phase/Status/Sponsor: Unknown phase; COMPLETED; Palleos Healthcare GmbH.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Study of Surgery and Radiotherapy in People With Breast Cancer is being studied. Conditions: Metastatic Breast Cancer, HER2-positive Breast Cancer • Eligibility: Inclusion Criteria: * Age ≥ 18 years. * Pathologically-confirmed metastatic breast cancer. * Oligometastatic breast cancer (≤5 discrete metastatic lesions) without CNS involvement; as seen on standard imaging…. Goal: The researchers are doing this study to see if the combination of surgery, locoregional radiation therapy, SBRT (stereotactic body radiation therapy), and the usual approach is more effective in treating oligometastatic HER2-positive breast cancer than the usual approach alone. The researchers will also study the side effects of the study treatment. Phase/Status/Sponsor: Unknown phase; RECRUITING; Memorial Sloan Kettering Cancer Center.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Clinical Trial to Evaluate the Efficacy and Safety of TQB2102 for Injection Versus Investigator-Selected Chemotherapy in HER2 Low-Expressing Recurrent/Metastatic Breast Cancer is being studied. Conditions: Breast Cancer • Eligibility: Inclusion Criteria: * Subjects voluntarily enrolled in this study with good compliance; * Age: 18-75 years old; Eastern Cooperative Oncology Group Performance Status (ECOG PS) score: 0-1; *…. Goal: The study is a Phase III, randomized, multicenter, open-label study in HER2-low, HR+ metastatic breast cancer subjects who are patients with locally advanced or metastatic breast cancer with low HER2 expression in the recurrent metastatic stage who have not received chemotherapy. The primary objective of the study is to determine the efficacy and safety of TQB2102 compared to investigator-selected single-agent chemotherapy in the target population. Phase/Status/Sponsor: Unknown phase; NOT_YET_RECRUITING; Chia Tai Tianqing Pharmaceutical Group Co., Ltd..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Gedatolisib Plus Talazoparib in Advanced Triple Negative or BRCA1/2 Positive, HER2 Negative Breast Cancers is being studied. Conditions: TNBC - Triple-Negative Breast Cancer • Eligibility: Inclusion Criteria: Individuals from populations who are underrepresented in clinical research (e.g., racial and ethnic minorities, women, individuals from rural/frontier communities, older individuals) will be enrolled with a…. Goal: This study is designed to determine the RP2D of gedatolisib in combination with talazoparib and to evaluate the efficacy of this combination in advanced HER2 negative breast cancer that is triple negative or BRCA1/2 positive (deficient). Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; Kari Wisinski.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

T-DM1 Combined With CDK4/6 Inhibitor Ribociclib is being studied. Conditions: HER2-positive Advanced Breast Cancer • Eligibility: Inclusion Criteria: * Age ≥18 at the time of signing the informed consent. * Patient's ability to follow the study protocol as determined by the investigator. * A…. Goal: To explore the efficacy and safety of T-DM1 combined with CDK4/6 inhibitor Ribociclib in the treatment of HER2-positive advanced breast cancer. Phase/Status/Sponsor: Unknown phase; ENROLLING_BY_INVITATION; Zheng Yabing.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

This Mayo Clinic-sponsored trial, currently recruiting, tests delivering cancer treatment at home versus in the clinic for adults with advanced cancer who are already receiving standard therapy. It aims to learn how the home-based approach affects patient experiences, preferences, comfort with home infusions, and overall quality of life compared with usual clinic care. The study also looks at safety of home administration with remote monitoring, and outcomes like emergency room visits, hospitalizations, and overall survival. Eligible participants are adults with various cancer types on eligible regimens, but those who need 24/7 assistance with daily activities, are currently inpatient, or have uncontrolled illness may be excluded.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Evaluation of the Cardioprotective Effect of Nebivolol on Trastuzumab-Induced Cardiotoxicity in Breast Cancer Patients is being studied. Conditions: HER2-positive Breast Cancer • Eligibility: Inclusion Criteria: * Age ≥18 years old. * Newly diagnosed with early or locally advanced HER2 positive breast cancer. * Normal baseline LVEF (˃50%) * Planned to receive…. Goal: Breast cancer can be managed using chemotherapy, endocrine therapy and biological therapy. Treatment is determined and specified according to the characteristics of the tumor including overexpression of the human epidermal growth factor receptor (HER2). Phase/Status/Sponsor: Unknown phase; RECRUITING; Ain Shams University.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Breast Cancer Evolution During Neoadjuvant Systemic Therapy is being studied. Conditions: Breast Cancer, Triple Negative Breast Cancer, ER+ Breast Cancer +1 • Eligibility: Inclusion Criteria: 1. Histologically confirmed non-metastatic invasive breast cancer. 2. Be suitable for, but have not commenced, neoadjuvant chemotherapy, targeted therapy, or immunotherapy. 3. If HER2-, suitable for…. Goal: BELIEVE is a translational research study that aims to collect samples of breast cancer tissue and blood from individuals undergoing breast cancer treatment (such as chemotherapy, targeted therapy and immunotherapy) before surgery. In certain cases, MRI scans and stool samples will also be obtained before and during treatment. Phase/Status/Sponsor: Unknown phase; RECRUITING; Royal Marsden NHS Foundation Trust.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

This phase II trial tests whether a blood test that measures circulating tumor DNA (ctDNA) can guide changes in standard chemotherapy for metastatic triple-negative breast cancer, and whether this approach works better than decisions based on imaging alone. It is for adults with metastatic TNBC whose disease is measurable and who have not yet had chemotherapy for metastatic disease. The study aims to learn if ctDNA changes can predict treatment failure early and whether changing therapy based on ctDNA results (including possible use of sacituzumab govitecan) can improve progression-free survival and other outcomes. Key exclusions include leptomeningeal disease, uncontrolled pain or hypercalcemia, recent or active other cancers, pregnancy, and significant uncontrolled health problems.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Neoadjuvant Complete Response Customized Treatment Approach for Definitive Management of Breast Cancer is being studied. Conditions: Breast Cancer, HER2-positive Breast Cancer, Triple Negative Breast Cancer • Eligibility: Inclusion Criteria: 1. Provision of signed and dated informed consent form 2. Stated willingness to comply with all study procedures and availability for the duration of the study…. Goal: This study will evaluate the efficacy and non-inferiority of a non-surgical approach for the treatment of patients with locally advanced breast cancer. Phase/Status/Sponsor: Unknown phase; NOT_YET_RECRUITING; Ohio State University Comprehensive Cancer Center.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Early Access Program Providing HER2/HER3 Bispecific Antibody, MCLA-128, for a Patient With Advanced NRG1-Fusion Positive Solid Tumor is being studied. Conditions: NRG1 Fusion, Pancreatic Cancer, Non Small Cell Lung Cancer +8 • Eligibility: Inclusion Criteria: * Age 18 years or older * At least one evaluable or measurable lesion according to RECIST v1.1 * Patient with advanced metastatic solid tumor with…. Goal: Merus is providing single patient/named access to the HER2/HER3 bispecific antibody, MCLA-128, to patients with advanced NRG1-fusion positive solid tumor under this early access program who are ineligible for an ongoing MCLA-128 clinical trial or have other considerations that prevent access to MCLA-128 through an existing clinical trial. Participating sites will be added as they apply for and are approved for the EAP. Phase/Status/Sponsor: Unknown phase; APPROVED_FOR_MARKETING; Merus B.V..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Phase 1 Study of SHR-A1811 in Patients With Selected HER2 Expressing Tumors is being studied. Conditions: Gastric Cancer, Colorectal Cancer • Eligibility: Inclusion Criteria: * Has a pathologically or cytologically documented advanced/unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma and colorectal cancer that is refractory to or intolerable with standard…. Goal: This is a single arm, open-label, dose escalation, PK expansion and efficacy expansion study of phase I. The purpose of this study is to assess the tolerability, safety, pharmacokinetics and immunogenicity of SHR-A1811 and preliminary anti-tumor efficacy in HER2-expressing advanced gastric or gastroesophageal junction adenocarcinoma and colorectal cancer. Phase/Status/Sponsor: Unknown phase; COMPLETED; Jiangsu HengRui Medicine Co., Ltd..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Study of RC48-ADC Combined With Pyrotinib For Treatment of Local Advanced or Metastasis NSCLC With HER2 Mutation is being studied. Conditions: Non-small Cell Lung Cancer • Eligibility: Inclusion Criteria: * Voluntary agreement to provide written informed consent. * Predicted survival ≥ 12 weeks. * According to UICC/AJCC 8th Edition, histologically and/or cytologically-confirmed, cannot be surgically…. Goal: This study will evaluate the efficacy, safety and pharmacokinetics of RC48-ADC for injection combined with pyrotinib in subjects with local advanced or metastatic non-small cell lung cancer with HER2 mutation. Phase/Status/Sponsor: Unknown phase; UNKNOWN; RemeGen Co., Ltd..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

- The trial tests Sapu003 in adults with advanced mTOR-sensitive solid tumors, in two groups: Cohort A will receive Sapu003 with exemestane for HR+/HER2-negative breast cancer, and Cohort B will receive Sapu003 alone for RCC, NETs, TSC-associated tumors, or HCC. - This is a phase 1b, open-label, dose-escalation study to find the maximum tolerated dose and to assess safety, pharmacokinetics, and any early antitumor activity. - Eligibility includes adults 18 years or older with the specified cancers, ECOG 0–2, and adequate organ function; key exclusions include active brain metastases, uncontrolled infections or other serious conditions, HIV/HBV/HCV infection, recent major surgery, and pregnancy or breastfeeding. - Sapu003 will be given as weekly IV infusions at 5, 7.5, or 10 mg/m2 in 28-day cycles.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Efficacy of T-Dxd in the Treatment of HER2-positive BCBM After Prior Pyrotinib is being studied. Conditions: Breast Cancer • Eligibility: Inclusion Criteria: (1) Women ≥18 years of age :(2) pathological diagnosis of HER2-positive breast cancer, defined as positive immunohistochemistry detection (+++) or FISH(Fluorescent In Situ Hybridization); (3) Imaging…. Goal: To evaluate the efficacy and safety of T-DXd in the treatment of HER2-positive breast cancer with brain metastases after treatment with pyrotinib Phase/Status/Sponsor: Unknown phase; UNKNOWN; Beijing 302 Hospital.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Study Assessing Risk Factors for Oral Mucositis/Stomatitis and Ocular Surface Events in NSCLC and Breast Cancer is being studied. Conditions: Advanced/Metastatic NSCLC, Advanced/Metastatic HER2-negative Breast Cancer • Eligibility: Inclusion Criteria 1. The inclusion criteria for the NSCLC cohort consists of patients with advanced or metastatic (stage IIIB/IIIC or IV) NSCLC diagnosis between January 1, 2015 and…. Goal: This study will identify risk factors for oral mucositis/stomatitis and ocular surface events (OSE) in patients with advanced/metastatic non-small cell lung cancer (NSCLC) and advanced/metastatic human epidermal growth factor receptor 2 (HER2)-negative breast cancer. Phase/Status/Sponsor: Unknown phase; COMPLETED; Daiichi Sankyo.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

This is a first-in-human study of VVD-159642, a RAS-PI3Kα inhibitor, in adults with advanced solid tumors. It aims to evaluate safety and tolerability, plus how the drug behaves in the body (PK/PD), and to see any early anti-tumor activity, both by itself and in combination with sotorasib or trametinib. Eligible participants include people with pancreatic ductal adenocarcinoma, colorectal cancer, non-small cell lung cancer, or any solid tumor with RAS alterations (KRAS, NRAS, HRAS), or with EGFR alterations or HER2 overexpression. Key exclusions include active CNS cancers, significant cardiac disease, uncontrolled hypertension, inflammatory bowel disease or malabsorption issues, and active hepatitis B or C infections.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Study Aiming to Compare the Plasma Exposure of the Payload (Free-DXd) in Patients Treated by T-DXd for Locally Advanced or Metastatic Breast Cancer According to Their BMI. is being studied. Conditions: Locally Advanced or Metastatic Breast Cancers • Eligibility: Inclusion Criteria: 1. Women (or men) aged ≥ 18 years on the day of signing the informed consent with histologically proven breast cancer. 2. Metastatic or locally advanced…. Goal: This is a multicenter, prospective, non-randomized, open-label, pharmacokinetic study, aiming to compare the plasma exposure of the payload (free-DXd) in patients treated by T-DXd for locally advanced or metastatic breast cancer according to their BMI. The primary objective is to compare plasma exposition of the payload (free-DXd) between overweight or obese (BMI\>25) and normal weight (BMI≤25) breast cancer patients during the first 3 cycles of Trastuzumab-Deruxtecan (T-DXd). Phase/Status/Sponsor: Unknown phase; RECRUITING; Institut Claudius Regaud.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Safety and Efficacy Study of NUV-1511 in Adult Patients With Advanced Solid Tumors is being studied. Conditions: Advanced Solid Tumor, HER2-negative Breast Cancer, Metastatic Castration-resistant Prostate Cancer (mCRPC) +2 • Eligibility: Inclusion Criteria: * Phase 1 Dose Escalation cohorts, Phase 1 Backfill cohorts, and Phase 2 Tumor Type-Specific cohort(s): must meet one of the following criteria: * HER2- metastatic…. Goal: NUV-1511-01 is a first-in human, open- label, Phase 1/2 to evaluate the safety and efficacy of NUV-1511 in patients with advanced solid tumors. The Phase 1 portion include patients with advanced solid tumors and is designed to determine the safety and the tolerability of doses of NUV-1511. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; Nuvation Bio Inc..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

The study tests Felmetatug Vedotin (SGN-B7H4V), given alone or with pembrolizumab, to see if it is safe and what side effects it may have in people with advanced solid tumors. It is for adults with locally advanced unresectable or metastatic cancers, including certain ovarian/peritoneal cancers, HER2-negative breast cancer, triple-negative breast cancer, endometrial cancer, some lung cancers, cholangiocarcinoma/gallbladder cancer, and adenoid cystic carcinoma. The trial has five parts to find the right dose, assess safety and activity, study the combination with pembrolizumab, and evaluate safety and efficacy in triple-negative breast cancer. Eligibility includes measurable disease and good functioning (ECOG 0–1) with tumor tissue available; key exclusions are a new cancer within 3 years (with some exceptions), active brain metastases, prior MMAE- or B7-H4-targeting therapy, neuropathy ≥ grade 2, or corneal disease. Status: Terminated.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Impact of Endocrine Therapy and Abemaciclib on Host and Tumor Immune Cell Repertoire/Function in Advanced ER+/HER2- Breast Cancer is being studied. Conditions: Metastatic Breast Cancer, Locally Advanced Breast Cancer, Hormone Receptor Positive Tumor • Eligibility: Inclusion Criteria: 1. Women age ≥ 18 2. Locally advanced/unresectable or metastatic breast cancer 3. Histologically documented estrogen receptor positive adenocarcinoma of the breast that is (any progesterone…. Goal: The purpose of this study is to perform an in depth analysis of changes in the tumor immune microenvironment in patients undergoing treatment with standard of care endocrine therapy and abemaciclib in the advanced setting via singe cell RNA sequencing. The investigators will also correlate changes in serum estrogen levels to changes in tumor and peripheral immune cell repertoire and function (including regulatory T cell populations, B cells, myeloid-derived suppressor cell populations, T cell activation and T cell exhaustion).This study has two cohorts with 15 patients in each cohort. Phase/Status/Sponsor: Unknown phase; COMPLETED; Duke University.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) is being studied. Conditions: Advanced Solid Tumor, Advanced Malignant Neoplasm, Metastatic Cancer +27 • Eligibility: Inclusion Criteria: * At least 18 years of age or 12 to 17 years of age after Safety Review Committee approval. * Locally advanced or metastatic solid malignancy…. Goal: The Phase 2 monotherapy portion of this study is currently enrolling and will evaluate the efficacy and safety of PC14586 (INN rezatapopt) in participants with locally advanced or metastatic solid tumors harboring a TP53 Y220C mutation. The Phase 1 portion of the study will assess the safety, tolerability and preliminary efficacy of multiple dose levels of rezatapopt as monotherapy and in Phase 1b in combination with pembrolizumab. Phase/Status/Sponsor: Unknown phase; RECRUITING; PMV Pharmaceuticals, Inc.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

DZD1516 in Combination With Trastuzumab and Capecitabine, or in Combination With T-DM1, in Patients With Metastatic HER2 Positive Breast Cancer is being studied. Conditions: Breast Cancer Metastatic • Eligibility: Inclusion Criteria: * Signed informed consent. * Male or female patients aged ≥ 18 years * histologically or cytologically confirmed HER2 positive advanced breast cancer which failed prior…. Goal: DZD1516 is an oral, blood brain barrier penetrable, selective HER2 tyrosine kinase inhibitor. This study is designed to evaluate the safety and tolerability of DZD1516 in patients with metastatic HER2 positive breast cancer who have progressed following prior therapy. Phase/Status/Sponsor: Unknown phase; COMPLETED; Dizal Pharmaceuticals.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

The XENERA™ 1 Study Tests Xentuzumab in Combination With Everolimus and Exemestane in Women With Hormone Receptor Positive and HER2-negative Breast Cancer That Has Spread is being studied. Conditions: Breast Neoplasms • Eligibility: Inclusion Criteria: * Documented histologically confirmed breast cancer with ERand/ or PgR-positive and HER2-negative status * Locally advanced or metastatic breast cancer not deemed amenable to curative surgery…. Goal: The main objective of the trial is to assess the efficacy of xentuzumab in combination with everolimus and exemestane over everolimus and exemestane in patients with HR+/ HER2- advanced or metastatic breast cancer and non-visceral disease. Phase/Status/Sponsor: Unknown phase; COMPLETED; Boehringer Ingelheim.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Pharmacokinetic Study of Pyrotinib and Docetaxel in Combination With Trastuzumab in Patients With HER2 Metastatic Breast Cancer is being studied. Conditions: Metastatic Breast Cancer • Eligibility: Inclusion Criteria: 1. HER2 positive recurrent or metastasis breast cancer. 2. Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1. 3. Adequate organ function. 4. Signed, written…. Goal: The primary objective of the study is to study the pharmacokinetics of pyrotinib and docetaxel plus Trastuzumab in HER2 Positive MBC. The secondary objective of the study is to evaluate the safety and efficacy (ORR) of pyrotinib and docetaxel plus Trastuzumab in HER2 Positive MBC. Phase/Status/Sponsor: Unknown phase; COMPLETED; Jiangsu HengRui Medicine Co., Ltd..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Afatinib in NSCLC With HER2 Mutation is being studied. Conditions: Carcinoma, Non-Small-Cell Lung • Eligibility: Inclusion criteria: * Patients with Histologically or cytologically confirmed diagnosis of stage IIIb/IV NSCLC (AJCC 7.0), who had failed one or two systemic chemotherapy regimens, one of which…. Goal: to investigate effectiveness and safety of afatinib in the advanced NSCLC patients with HER2 mutations, previously treated with 1 or 2 chemotherapy regimens Phase/Status/Sponsor: Unknown phase; COMPLETED; Boehringer Ingelheim.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

The PRE-I-SPY Phase I/Ib trial is an open-label, multisite platform study that tests single drugs or drug combinations in metastatic cancer with potential relevance to breast cancer. It runs multiple treatment arms, each with a possible dose-finding part and a dose-expansion part, and eligibility can vary by arm. The goal is to identify regimens that look promising and move them into the I-SPY 2 SMART Design Trial or other oncology trials, with analysis of each arm in about 12–18 months. Common exclusions include uncontrolled illness, significant cardiovascular or liver issues, active CNS metastases, recent major surgery, pregnancy, or use of other investigational therapies; arm-specific exclusions may also apply.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Testing Two Different Drugs (Sacituzumab-govitecan and Trastuzumab-deruxtecan) Combinations Prescribed in an Alterning Pattern to Patients With Metastatic or Locally Advanced Triple-negative Breast Cancer is being studied. Conditions: Triple Negative Breast Neoplasms, Neoplasm Metastasis, HER 2 Low-expressing Breast Cancer • Eligibility: Inclusion Criteria: * Patient must have signed a written informed consent prior to any trial specific procedures. (Note : When the patient is physically unable to give his/her…. Goal: This is a phase II, multicentre, open-label, randomised controlled trial (patients are randomly assigned to one treatment arm or the other) evaluating two treatment strategies (sacituzumab govitecan and trastuzumab deruxtecan in an alternative schema or sacituzumab govitecan alone) in patients with locally advanced or metastatic triple-negative breast cancer. The goal is to answer the question: Does alternating sacituzumab goveitecan (SG) and trastuzumab deruxtecan (T-DXd) improve survival in patients with HER2-low metastatic triple-negative breast cancer compared to continuing treatment with SG alone? Phase/Status/Sponsor: Unknown phase; NOT_YET_RECRUITING; UNICANCER.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Prospective, Open-label, Exploratory Basket Trial to Evaluate the Efficacy and Safety of Sintilimab Combined With Pyrotinib ± Chemotherapy in Patients With Advanced Digestive System Tumors is being studied. Conditions: Advanced Digestive System Tumor • Eligibility: Inclusion Criteria: * Age ≥18 years * Patients with unresectable locally advanced T3-4 stage or M1 stage metastatic digestive system tumors confirmed by histology or cytology, including gastric…. Goal: This is a prospective, open-label, exploratory, phase II basket clinical trial designed to evaluate the efficacy and safety of sintilimab in combination with pyrotinib with or without chemotherapy in patients with advanced HER2-positive digestive system malignancies. Eligible patients include those with locally advanced unresectable or metastatic gastric, colorectal, hepatocellular, biliary tract, or pancreatic cancers. Phase/Status/Sponsor: Unknown phase; NOT_YET_RECRUITING; Tongji Hospital.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

IMaging PAtients for Cancer Drug selecTion - Metastatic Breast Cancer is being studied. Conditions: Metastatic Breast Cancer • Eligibility: Inclusion Criteria: * Patient with first presentation of MBC, regardless of ER and HER2 status of the primary tumor, who is eligible for first-line systemic therapy. * Patient…. Goal: Current patient work-up, including conventional imaging and pathological assessment of just one single biopsy, might be insufficient to identify metastatic breast cancer patients, who possibly benefit from first-line anti-hormonal or anti-HER2 therapy. As receptor conversion of the tumor is found quite frequently and molecular heterogeneity can occur within one patient, up-to-date whole body information is necessary to determine estrogen receptor (ER) and/or human epidermal growth factor receptor 2 (HER2) receptor status and subsequently guide therapy decision. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; University Medical Center Groningen.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors is being studied. Conditions: Solid Tumor, Advanced Solid Tumor, Solid Tumor, Adult +25 • Eligibility: Inclusion Criteria: \- Must have a pathologically confirmed advanced and unresectable or metastatic solid tumor listed below with documented disease progression on last standard treatment. Part 1 only:…. Goal: The goal of the Dose Escalation phase of the study is to evaluate the safety, tolerability, pharmacokinetics (PK) and preliminary anti-tumor activity to determine the preliminary recommended dose for expansion (RDE) of NKT3964 in adults with advanced or metastatic solid tumors. The goal of the Expansion phase of the study is to evaluate the preliminary anti-tumor activity of NKT3964 at the RDE based on objective response rate (ORR) and determine the preliminary recommended Phase 2 dose (RP2D). Phase/Status/Sponsor: Unknown phase; RECRUITING; NiKang Therapeutics, Inc..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

FTT PET/CT in Pancreatic Neuroendocrine Tumors is being studied. Conditions: Neuroendocrine Carcinoma Metastatic, Pancreatic Tumors • Eligibility: Inclusion Criteria: 1. Patients must be ≥ 18 years of age. 2. Clinical diagnosis of a metastatic or unresectable grade 1, grade 2 or grade 3 (G1/G2/G3) pancreatic…. Goal: A pilot study to evaluate the expression of PARP-1 in patients with pancreatic neuroendocrine tumors will be conducted. This will be done via the use of a novel PET imaging agent, \[18F\]FluorThanatrace (\[18F\]FTT). Phase/Status/Sponsor: Unknown phase; RECRUITING; Abramson Cancer Center at Penn Medicine.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

PTEN and Organ-Specific microRNAs in Metastatic Breast Cancer is being studied. Conditions: Breast Cancer, Metastatic Breast Cancer, miRNAs +1 • Eligibility: Inclusion Criteria: * Female individuals aged ≥18 years * Ability to provide written informed consent * Group I (Metastatic BC): Histopathologically confirmed breast cancer and radiologically or clinically…. Goal: This prospective observational study aims to evaluate serum levels of PTEN, a tumor suppressor gene, and organ-specific microRNAs (miRNAs) associated with metastatic patterns in breast cancer. Serum samples will be analyzed using quantitative reverse transcription polymerase chain reaction (qRT-PCR)-based miRNA profiling and enzyme-linked immunosorbent assay (ELISA)-based PTEN quantification. Phase/Status/Sponsor: Unknown phase; RECRUITING; Atlas University.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

This trial tests nanvuranlat in adults with biliary tract cancer to find a recommended dose regimen (Part A) and to study its effect on overall survival compared with the physician’s best choice (Part B). Participants are 18 years or older with advanced, metastatic, or unresectable BTC who have received one prior platinum-based therapy. Treatments are given every two weeks with safety checks, tumor imaging, and exploratory tests to understand how the drug works. Key exclusions include active CNS metastases, significant cardiovascular disease, HIV not on therapy, active HBV or HCV infection, and pregnancy.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

- This study tests BOLD-100 given with the chemotherapy FOLFOX in adults with advanced gastrointestinal cancers (such as colorectal, pancreatic, gastric cancers, and cholangiocarcinoma) to assess safety and tolerability, using a dose-escalation phase followed by expansion. - In the colorectal cancer arm (Arm VII), eligible patients who are oxaliplatin-naïve and have had only one prior metastatic therapy will be randomized to three groups: BOLD-100 at 500 mg/m2 with FOLFOX, BOLD-100 at 625 mg/m2 with FOLFOX, or FOLFOX alone, with quality-of-life assessments. - The trial aims to learn whether adding BOLD-100 provides anti-tumor activity and how it affects patients’ quality of life, while establishing safe dose levels. - Key exclusions include neuropathy greater than grade 2, CNS metastases, active HIV on ART, DPD deficiency, prior exposure to BOLD-100 (for Arm VII), MSI-H tumors, and recent major treatments or other serious conditions.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

DESTINY-PANTUMOUR04 is being studied. Conditions: Adenocarcinoma (NOS), Anal Cancer, Bladder Cancer +24 • Eligibility: Inclusion Criteria: 1. Adults aged ≥18 years 2. Patients with locally advanced, unresectable, or metastatic HER2-positive (IHC 3+) solid tumors who have received prior systemic treatment for metastatic…. Goal: This study will evaluate the effectiveness of T-DXd in patients with HER2-positive (IHC 3+) locally advanced, unresectable, or metastatic solid tumors who have received prior systemic treatment for metastatic or advanced disease and have no satisfactory alternative treatment options in a real-world setting in the US Phase/Status/Sponsor: Unknown phase; RECRUITING; AstraZeneca.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Study of ASP2138 Given by Itself or Given With Other Cancer Treatments in Adults With Stomach Cancer, Gastroesophageal Junction Cancer, or Pancreatic Cancer is being studied. Conditions: Gastric Adenocarcinoma, Gastroesophageal Junction (GEJ) Adenocarcinoma, Pancreatic Adenocarcinoma • Eligibility: Inclusion Criteria: * Participant is considered an adult according to local regulation at the time of signing the informed consent form (ICF). * Female participant is not pregnant,…. Goal: Claudin 18.2 protein, or CLDN18.2 is a protein found on cells in the digestive system. It is also found on some tumors. Phase/Status/Sponsor: Unknown phase; RECRUITING; Astellas Pharma Global Development, Inc..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Study of LY4337713 in Participants With FAP-Positive Solid Tumors is being studied. Conditions: Ovarian Neoplasms, Breast Neoplasms, Pancreatic Intraductal Neoplasms +4 • Eligibility: Inclusion Criteria: * Must have clinical or imaging evidence of fibroblast activation protein (FAP) expression per local assessment * Must have histologically or cytologically confirmed diagnosis of one…. Goal: This is a study of LY4337713 in participants with certain types of cancer that is advanced or has spread. Participants must have cancer with high levels of a protein called fibroblast activation protein (FAP). Phase/Status/Sponsor: Unknown phase; RECRUITING; Eli Lilly and Company.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Target-specific immunoPET Imaging of Digestive System Carcinoma is being studied. Conditions: Malignancy, Digestive Cancer, Digestive System Neoplasm +12 • Eligibility: Inclusion Criteria: 1. Aged 18-75 years old and of either sex； 2. Histologically confirmed diagnosis of digestive system carcinoma or suspected digestive system carcinoma by diagnostic imaging; 3.…. Goal: The aim of this study is to establish and optimize the target-specific PET/CT imaging method, and its physiological and pathological distribution characteristics, on the basis of which the diagnostic efficacy of the above imaging agents in digestive system malignant tumors will be evaluated. Phase/Status/Sponsor: Unknown phase; RECRUITING; RenJi Hospital.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Identification and Treatment Of Micrometastatic Disease in Stage III Colon Cancer is being studied. Conditions: Metastatic Colon Cancer, Stage III Colon Cancer • Eligibility: Inclusion Criteria: * Participants must have histologically confirmed resected Stage III adenocarcinoma of the colon. Any T \[Tx, T1, T2, T3, or T4-\], N1-2M0. * Participants must have…. Goal: This research study is comparing two standard of care treatment options based on blood test results for participants who have metastatic colon cancer. The names of the potential treatments involved in this study are: * Active surveillance * FOLFIRI treatment * Nivolumab treatment * Encorafenib/Binimetinib/Cetuximab treatment * Trastuzumab + Pertuzumab Phase/Status/Sponsor: Unknown phase; RECRUITING; Massachusetts General Hospital.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

The trial tests TT-00420 (Tinengotinib) as a tablet given alone and in combination for adults with advanced solid tumors. It has three arms: Arm A tests TT-00420 alone in various advanced cancers; Arm B combines TT-00420 with atezolizumab for advanced biliary tract cancer; Arm C combines TT-00420 with nab-paclitaxel for advanced triple-negative breast cancer. The study is a Phase Ib/II, multicenter, open-label trial that aims to find a safe and tolerable dose for the next phase and then evaluate preliminary efficacy in each arm. Eligibility includes adults 18 or older with measurable disease and adequate organ function; key exclusions include pregnancy, active HIV/HBV/HCV infection, significant heart problems or QT prolongation, active brain metastases, and recent systemic anticancer therapy or conflicting medications. Status: COMPLETED. Sponsor: TransThera Sciences (Nanjing), Inc.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

- This study tests amivantamab plus FOLFIRI versus cetuximab/bevacizumab plus FOLFIRI in people with KRAS/NRAS and BRAF wild-type colorectal cancer who have previously received chemotherapy. - It aims to learn whether the amivantamab combination improves progression-free survival and overall survival compared with the cetuximab/bevacizumab combination. - Eligible participants have recurrent, unresectable, or metastatic colorectal cancer with confirmed KRAS/NRAS and BRAF wild-type status, have had at least one prior systemic therapy for metastatic disease, and have ECOG 0–1. - Key exclusions include preexisting interstitial lung disease/pneumonitis, allergies to study drugs, prior exposure to irinotecan or EGFR/MET inhibitors, HER2-positive tumors, or another active malignancy.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

This study tests whether camrelizumab (SHR-1210) plus apatinib can extend overall survival in people with advanced gastric or gastroesophageal junction adenocarcinoma whose disease progressed after first-line platinum-based therapy. It targets adults with metastatic or unresectable disease and PD-L1–positive tumors, who have good performance status and adequate organ function. The trial aims to learn if the combination is more effective and safe, and will collect PD-L1 biomarker data from tumor tissue. Key exclusions include active CNS metastases or autoimmune disease, uncontrolled cardiovascular issues, recent major GI bleeding or thrombosis, prior anti-PD-1/PD-L1 or VEGFR inhibitor therapy, and recent systemic therapy or unresolved adverse events.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Safety and Tolerability of ²¹²Pb-DOTAM-GRPR1 in Adult Subjects With Recurrent or Metastatic GRPR-expressing Tumors is being studied. Conditions: Cervical Cancer, Breast Cancer, Colon Cancer +4 • Eligibility: 1. Adult participants (age ≥ 18 years old) with any of the following advanced or metastatic solid tumors (documented history of histologically confirmed diagnosis): 1. Metastatic castration-resistant prostate…. Goal: A Phase 1 Open-Label, First-in-human, Dose Escalation and Expansion Study to Determine the Safety, Tolerability, Dosimetry, Pharmacokinetics, and Preliminary Efficacy of 212Pb-DOTAM-GRPR1 in Adult Participants with Recurrent or Metastatic GRPR-expressing Tumors Phase/Status/Sponsor: Unknown phase; RECRUITING; Orano Med LLC.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Abemaciclib Dose Escalation to Maintain Intensity (ADE-MI) is being studied. Conditions: Breast Cancer • Eligibility: Inclusion Criteria: * ECOG 0-2 * Histologically confirmed early-stage HR+HER2- breast cancer documented by biopsy who are prescribed adjuvant abemaciclib * Able to provide written informed consent and…. Goal: This is a post-marketing single arm, phase IV trial in which patients with high-risk early-stage HR+HER2- breast cancer will receive adjuvant abemaciclib in combination with endocrine therapy (ET) After study intervention, participants will remain on combination abemaciclib + ET at the discretion of their treating providers Phase/Status/Sponsor: Unknown phase; RECRUITING; University of Illinois at Chicago.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry is being studied. Conditions: Cancer, Metastatic, Cancer, Cancer of Pancreas +40 • Eligibility: Inclusion Criteria: * Pts with solid and hematological malignancies; * Pts cancer-related biomarkers, gene variants, fusion and rearrangements (by immunohistochemistry, PCR, FISH or NGS): PD-L1, MSI (MMR), Claudin18.2,…. Goal: International registry for cancer patients evaluating the feasibility and clinical utility of an Artificial Intelligence-based precision oncology clinical trial matching tool, powered by a virtual tumor boards (VTB) program, and its clinical impact on pts with advanced cancer to facilitate clinical trial enrollment (CTE), as well as the financial impact, and potential outcomes of the intervention. Phase/Status/Sponsor: Unknown phase; RECRUITING; Massive Bio, Inc..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

PIK3CA/PTEN-altered Advanced Breast Cancer Treated With MEN1611 Monotherapy or in Combination With Eribulin is being studied. Conditions: Breast Cancer, Advanced Breast Cancer, Metastatic Breast Cancer • Eligibility: General inclusion criteria PRE-SCREENING PHASE The following criteria must be met to be eligible to entry into the pre-screening: 1. Patient must be able to sign written pre-screening…. Goal: The multicenter, two-cohort, non-comparative, open-label, phase II clinical trial SABINA aims to analyze the safety and efficacy of MEN1611 in monotherapy and in combination with eribulin, a non-taxane chemotherapy agent, in Hormone Receptor (HR)-known/Human Epidermial Growth Factor Receptor 2 (HER2)-negative, phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha (PIK3CA)/ Phosphatase and Tensin Homolog (PTEN)-altered, unresectable locally advanced or metastatic metaplastic breast carcinoma (MpBC) patients. A run-in phase for safety and tolerability of MEN1611 in combination with standard doses of eribulin will be conducted as an initial step of the cohort A. Phase/Status/Sponsor: Unknown phase; RECRUITING; MedSIR.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A First-in-Human Escalation and Expansion Study of Patients With Advanced Solid Tumors is being studied. Conditions: Solid Tumors, Gastric Cancer, Esophagogastric Juction Cancer +1 • Eligibility: Inclusion Criteria Patients who meet ALL the following inclusion criteria will be eligible to participate in the study: 1. ≥18 years of age. 2. Histologically confirmed, locally advanced,…. Goal: The goal of this clinical trial is to learn if the investigational drug (JR8603) is safe and effective in treating patients with solid tumors after their initial rounds of treatment with other drugs did not work. Phase/Status/Sponsor: Unknown phase; RECRUITING; JiaRay Group.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Phase II Protocol of Proton Therapy for Partial Breast Irradiation in Early Stage Breast Cancer is being studied. Conditions: Breast Cancer, Breast Neoplasm, Breast Tumor +1 • Eligibility: Inclusion Criteria: * Must sign study-specific, IRB approved informed consent form prior to study entry. Note consent by legally authorized representative is not allowed for this trial. *…. Goal: The purpose of this research study is to compare the effects (good and bad) on women and their cancer using proton radiation therapy. This study is being done to see if proton radiation therapy will prove to be beneficial for women with early stage breast cancer. Phase/Status/Sponsor: Unknown phase; RECRUITING; Proton Collaborative Group.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Efficacy of Tislelizumab and Spartalizumab Across Multiple Cancer-types in Patients with PD1-high MRNA Expressing Tumors is being studied. Conditions: MSI-H Colorectal Cancer, Melanoma, Anal Carcinoma +28 • Eligibility: Inclusion Criteria: 1. Male/female participants who are at least 18 years of age on the day of signing informed consent with histologically confirmed diagnosis of PD1 mRNA high-expression…. Goal: This is an open-label, parallel group, non-randomized, multicenter phase II study to evaluate the efficacy of spartalizumab (cohorts 1 and 2) and tislelizumab (cohort 3) in monotherapy in patients with PD1-high-expressing tumors. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; SOLTI Breast Cancer Research Group.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Study of Zilovertamab Vedotin (MK-2140/VLS-101) in Participants With Solid Tumors (MK-2140-002) is being studied. Conditions: Triple-negative Breast Cancer, Non-squamous Non-small-cell Lung Cancer, NSCLC +12 • Eligibility: Inclusion Criteria: * Has a confirmed diagnosis of solid tumor for one of the following types of cancer: previously treated cancers of triple-negative breast cancer (TNBC), non-TNBC HER2-negative…. Goal: This is a study evaluating the efficacy, safety, and pharmacokinetics of zilovertamab vedotin in participants with metastatic solid tumors including previously treated cancers of triple-negative breast cancer (TNBC), non-TNBC human epidermal growth factor receptor 2 (HER2)-negative breast cancer, non-squamous non-small-cell lung cancer (NSCLC), gastric cancer, pancreatic cancer, and platinum-resistant ovarian cancer. The study will evaluate a null hypothesis that the objective response rate (ORR) is ≤5% against the alternative hypothesis that it is ≥20%. Phase/Status/Sponsor: Unknown phase; TERMINATED; VelosBio Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA).

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Study of XmAb®23104 in Subjects With Selected Advanced Solid Tumors (DUET-3) is being studied. Conditions: Melanoma (Excluding Uveal Melanoma), Cervical Carcinoma, Pancreatic Carcinoma +13 • Eligibility: Inclusion Criteria: 1. Subjects in Part A (dose escalation) must have a diagnosis of any of the following: Histologically or cytologically confirmed advanced solid tumors, including the following:…. Goal: This is a Phase 1, multiple dose, ascending dose escalation study to define a MTD/RD and regimen of XmAb23104, to describe safety and tolerability, to assess PK and immunogenicity, and to preliminarily assess anti-tumor activity of XmAb23104 monotherapy and combination therapy with ipilimumab in subjects with selected advanced solid tumors. Phase/Status/Sponsor: Unknown phase; COMPLETED; Xencor, Inc..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

The study tests zanzalintinib in combination with paclitaxel to find the best dose for the next phase in people with recurrent high-grade uterine cancer. It also aims to assess safety and tolerability and to learn how often tumors respond to the treatment. Eligible participants are adults with recurrent high-grade uterine cancer (including endometrioid, serous, mixed high-grade, or uterine carcinosarcoma) who progressed on or could not tolerate platinum therapy, with 1–2 prior cancer treatments and measurable disease. Key exclusions include prior exposure to zanzalintinib, known brain metastases unless adequately treated and stable, recent use of certain therapies, QT prolongation, pregnancy, and other conditions that could make participation unsafe.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Study of SYN818 With Olaparib for the Treatment of Locally Advanced or Metastatic Solid Tumors is being studied. Conditions: Metastatic Solid Tumor, Ovarian Cancer, Breast Cancer +2 • Eligibility: Inclusion Criteria: * Having signed the written Informed Consent Form (ICF); * Male or female aged ≥18 years; * Life expectancy ≥12 weeks; * Eastern Cooperative Oncology Group…. Goal: This interventional study will evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and preliminary efficacy of SYN818 with Olaparib in adult patients with locally advanced or metastatic solid tumors Phase/Status/Sponsor: Unknown phase; RECRUITING; Hangzhou SynRx Therapeutics Biomedical Technology Co., Ltd.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

HTL0039732 is a new drug being tested in adults with advanced solid tumors, given alone or with atezolizumab or other approved cancer therapies. This is a first-in-human, early-phase study to find safe dose levels and to learn how the drug may affect tumors. In Phase 1 Part A, HTL0039732 is given as a monotherapy; in Phase 1 Part B it is given with atezolizumab, and Phase 2a will test the dose in specific cancer types where PGE2/EP4 signaling may be important. The study will also look at safety and potential side effects of HTL0039732 alone and in combination. Key exclusions include recent cancer therapies or immunotherapies, active autoimmune disease needing systemic treatment in the past 2 years, HIV or hepatitis B/C infection, pregnancy or breastfeeding, prior EP4 inhibitors, and receipt of live vaccines within 4 weeks before enrollment for parts involving immunotherapy.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Feasibility of a Preoperative, Multimodal Lifestyle Intervention in Patients With Breastcancer is being studied. Conditions: Breast Cancer, Breast Neoplasms • Eligibility: Inclusion Criteria: * Patients diagnosed with stage I-III breast cancer eligible for neoadjuvant intravenous chemotherapy at the MUMC+ * Aged ≥18 years * Eastern Cooperative Oncology Group (ECOG)…. Goal: The primary objective of this study is to investigate the feasibility of a multimodal prehabilitation programme consisting of MIET during neoadjuvant intravenous chemotherapy infusion, HITT and strength training during the last six weeks prior to surgery, and optimising nutritional intake throughout the total preoperative period in patients with breast cancer with respect to recruitment, adherence, dropout, safety and acceptance. The secondary objective is to provide a preliminary evaluation of participant responses to a preoperative multimodal lifestyle intervention, on cardiorespiratory fitness, muscle strength, nutritional status, and fatigue in patients with breast cancer receiving neoadjuvant chemotherapy. Phase/Status/Sponsor: Unknown phase; RECRUITING; Maastricht University Medical Center.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Study of MGD013 in Patients With Unresectable or Metastatic Neoplasms is being studied. Conditions: Advanced Solid Tumors, Hematologic Neoplasms, Ovarian Cancer +7 • Eligibility: Inclusion Criteria: * Histologically proven, locally advanced unresectable or metastatic solid tumors (or hematologic malignancies, Cohort Expansion only) for whom no approved therapy with demonstrated clinical benefit is…. Goal: The primary goal of this Phase 1 study is to characterize the safety and tolerability of tebotelimab and establish the maximum tolerated dose (MTD) of tebotelimab in advanced solid tumors, and tebotelimab in combination with margetuximab in HER2+ advanced solid tumors. Pharmacokinetics (PK), immunogenicity, pharmacodynamics (PD), and the anti-tumor activity of tebotelimab will also be assessed. Phase/Status/Sponsor: Unknown phase; COMPLETED; MacroGenics.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Study of Amivantamab and Olomorasib Combination Therapy in Participants With Metastatic Non-Small Cell Lung Cancer is being studied. Conditions: Carcinoma, Non-Small-Cell Lung • Eligibility: Inclusion criteria: * Participant must have histologically or cytologically confirmed metastatic NSCLC characterized by a KRAS G12C mutation at the time of enrollment. For Phase 1: Participant must…. Goal: The main purpose of this study is to find out the most suitable dose (recommended phase 2 combination dose \[RP2CD\]) of amivantamab and olomorasib combination therapy and to assess how well the combination slows down or prevents the growth of tumors in participants with KRAS G12C mutant metastatic non-small cell lung cancer (NSCLC: the most common type of lung cancer; metastatic: has spread to other parts of the body; KRAS G12C mutant: mutation \[change\] in the kirsten rat sarcoma viral oncogene homolog \[KRAS\] gene in tumor cells in which glycine \[G\] at position 12 is replaced with cystine \[C\]). Phase/Status/Sponsor: Unknown phase; RECRUITING; Janssen Research & Development, LLC.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Study of BL0175 Injection in Postmenopausal Female Adults With HR-positive, Locally Advanced or Metastatic Cancer is being studied. Conditions: Breast Cancer, Ovarian Cancer, Endometrial Cancer • Eligibility: Inclusion Criteria: 1. Volunteer to participate in the study, be able to understand the requirements of a clinical study, and willingness to sign a written informed consent form.…. Goal: The goal of this clinical trial is to learn if the investigational drug BL0175 works to treat adult postmenopausal women with hormone receptor (HR)-positive, human epidermal growth factor receptor (HER2)-negative locally advanced or metastatic breast cancer, ovarian cancer and endometrial cancer. It will also learn about the safety of BL0175. Phase/Status/Sponsor: Unknown phase; RECRUITING; Shanghai Best-Link Bioscience, LLC.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

EMB-01 in Patients With Advanced/Metastatic Gastrointestinal Cancers is being studied. Conditions: Neoplasms, Neoplasm Metastasis, Metastatic Gastrointestinal Carcinoid Tumor • Eligibility: Inclusion Criteria: Molecular Pre-screening Inclusion criteria 1. cMET amplification in tumor sample; OR 2. cMET overexpression in tumor sample; OR 3. EGFR overexpression in tumor sample; OR 4.…. Goal: This study is to evaluate the safety and antitumor activity of EMB-01 in advanced/metastatic gastrointestinal cancers, including gastric cancer, hepatocellular cancer, cholangiocarcinoma and colorectal cancer. Phase/Status/Sponsor: Unknown phase; RECRUITING; Shanghai EpimAb Biotherapeutics Co., Ltd..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Arm Swelling Occurence in Breast Cancer Patients With Nodal Radiotherapy: Impact of Informing Them of AI-predicted Risk is being studied. Conditions: Unilateral Breast Neoplasms • Eligibility: Inclusion Criteria: 1. Patient must have signed a written informed consent form prior to inclusion visit and to any study specific procedures 2. Women ≥ 18 years 3.…. Goal: Radiotherapy after breast cancer surgery can lead to side effects like arm lymphedema (arm swelling). Lymphedema can cause long-term discomfort and affect quality of life. Phase/Status/Sponsor: Unknown phase; RECRUITING; UNICANCER.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Pembrolizumab, Olaparib, Recurrent/Advanced Gastric and Gastro-esophageal Junction(GEJ) Cancer is being studied. Conditions: Gastric Cancer Stage IV • Eligibility: Inclusion Criteria: 1. Provided written informed consent for treatment. 2. Age ≥ 19 years old 3. measurable or evaluable disease based on RECIST 1.1. Lesions 4. Eastern Cooperative…. Goal: Pembrolizumab is a potent humanized immunoglobulin G4 (IgG4) monoclonal antibody (mAb) with high specificity of binding to the programmed cell death 1 (PD 1) receptor, thus inhibiting its interaction with programmed cell death ligand 1 (PD-L1) and programmed cell death ligand 2 (PD-L2). Olaparib is a potent PARP inhibitor (PARP1, 2, and 3) that is being developed as a monotherapy as well as for combination with chemotherapy, ionizing radiation, and other anti-cancer agents including novel agents and immunotherapy. Phase/Status/Sponsor: Unknown phase; RECRUITING; Yonsei University.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Olaparib is being studied. Conditions: Ovarian Cancer, Breast Cancer • Eligibility: Inclusion Criteria: 1. Provision of signed and dated, written ICF. 2. Patient is currently deriving clinical benefit, as judged by the Investigator, from continued treatment in an AZ…. Goal: The rationale of the ROSY-O study is to continue to provide study treatment for patients who have participated in a parent study with olaparib and who are continuing to derive clinical benefit from treatment at the end of such studies, as judged by the Investigator. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; AstraZeneca.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Precision Physical Exercise for Personalized Onco-Hematology. is being studied. Conditions: Hematologic Cancer, Colon Cancer, Breast Cancer +3 • Eligibility: Inclusión criteria: * Adult patients (≥18 years), capable of signing the informed consent and willing to participate in the study. * Performance status (ECOG) 0-2. * Specific inclusion…. Goal: Physical exercise, particularly strength training, has become an effective strategy to improve physical function, muscle mass, and quality of life in cancer patients. However, the biological mechanisms underlying these benefits remain poorly understood, especially during active treatment. Phase/Status/Sponsor: Unknown phase; NOT_YET_RECRUITING; University of Salamanca.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Study of Molecular Residual, Dynamic Monitoring and Recurrence of Stage III Driver Mutated NSCLC is being studied. Conditions: Non Small Cell Lung Cancer • Eligibility: Inclusion Criteria: 1. Patients with stage III non-small cell lung cancer were confirmed by imaging and histological biopsy 2. Age≥ 18 3. ECOG PS:0-1 4. Tumor molecular testing…. Goal: The goal of this prospective, observational study is to explore the value of dynamic monitoring of minimal residual lesions in driver mutated stage III NSCLC for disease recurrence and prognosis assessment. The main question it aims to answer is: 1\) Whether MRD(Minimal residual disease) status can predict recurrence events in stage III driven-mutant NSCLC in advance Phase/Status/Sponsor: Unknown phase; RECRUITING; Shanghai Chest Hospital.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

- This trial tests whether adding nimotuzumab to paclitaxel improves outcomes for second-line treatment of recurrent metastatic gastric or esophagogastric junction adenocarcinoma that over-expresses EGFR, against paclitaxel with placebo. - It is a randomized, double-blind, placebo-controlled Phase III study enrolling about 354 patients who have ECOG 0-1 and EGFR high expression. - The main goal is to measure overall survival, with secondary aims including progression-free survival, objective response rate, duration of response, disease control, quality of life, and safety. - Key exclusions include prior progression on paclitaxel or anti-EGFR therapy (or recent anti-EGFR/paclitaxel treatment), brain metastases, serious coexisting illnesses, active infections or hepatitis B/C, pregnancy, and known allergies to the study drugs.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

The Efficacy and Safety of IBI363 in Solid Tumors is being studied. Conditions: Advanced Solid Tumor • Eligibility: Inclusion Criteria: * Sign written informed consent before implementing any trial-related procedures * Age ≥18 years old and ≤75 years old; * No limit on the gender; *…. Goal: The study is a prospective multi-cohort clinical study. The study is divided into two phases, Phase Ia and Phase Ib. Phase/Status/Sponsor: Unknown phase; RECRUITING; Hunan Province Tumor Hospital.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Addition of Cisplatin to Adjuvant Chemotherapy for Early Stage Breast Cancer in High-Risk Women is being studied. Conditions: Tubular Breast Cancer, Mucinous Breast Cancer, Invasive Duct Carcinoma of Breast • Eligibility: Inclusion Criteria: 1. Women aged ≥18 years and ≤70 years 2. Have accepted surgical treatment, histologically confirmed early breast cancer, the pathological types of invasive carcinoma 3. Not…. Goal: The investigators hypotheses that paclitaxel combined with cisplatin in a weekly-based regimen as adjuvant chemotherapy is more effective for high risk, HER2 negative breast cancer . Phase/Status/Sponsor: Unknown phase; RECRUITING; RenJi Hospital.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

This study tests adding elimusertib (BAY 1895344) to standard chemotherapy with cisplatin, or cisplatin plus gemcitabine, for adults with advanced solid tumors, including urothelial cancer. It is a dose-escalation phase I trial to find the safest and most effective dose and to learn how the combination behaves in the body. The trial will assess safety and tolerability, identify the maximum tolerated dose, and collect pharmacokinetics and early signs of activity, with a focus on urothelial cancer in the triplet arm. Eligible participants are adults 18 or older with measurable advanced disease for which cisplatin-based therapy is suitable; key exclusions include pregnancy, life expectancy under 6 weeks, uncontrolled illness, recent chemotherapy or radiotherapy, and certain drug interactions or prior ATR inhibitors. The study is currently active but not recruiting.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Pembrolizumab in Treating Patients With Hormone Receptor Positive, Localized Inflammatory Breast Cancer Who Are Receiving Hormone Therapy and Did Not Achieve a Pathological Complete Response to Chemotherapy is being studied. Conditions: Anatomic Stage IIIB Breast Cancer AJCC v8, Anatomic Stage IIIC Breast Cancer AJCC v8, Breast Inflammatory Carcinoma +2 • Eligibility: Inclusion Criteria: 1. Is willing and able to provide written informed consent for the trial. 2. Is a female or male and \>/= 18 years of age 3.…. Goal: This phase II trial studies how well pembrolizumab works in treating patients with hormone receptor positive inflammatory breast cancer that has not spread to other parts of the body, who are receiving hormone therapy and did not achieve a pathological complete response to chemotherapy. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; M.D. Anderson Cancer Center.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Trilaciclib in Patients With Early-Stage HR-negative Breast Cancer Receiving Adjuvant Chemotherapy is being studied. Conditions: Breast Neoplasms • Eligibility: Inclusion Criteria: * age ≥ 18 years; * breast cancer meets the following criteria: * Histologically or cytologically confirmed and adequately resected non-metastatic primary invasive breast cancer; *…. Goal: The goal of this multicenter, two-cohort, exploratory clinical trial is to evaluate patients with early stage hormone receptor-negative breast cancer receiving standard adjuvant chemotherapy after surgery. The main question it aims to answer is: • The efficacy and safety of trilaciclib administered before standard adjuvant chemotherapy regimen using the incidence of grade 3/4 neutropenia as the primary efficacy endpoint. Phase/Status/Sponsor: Unknown phase; RECRUITING; wang shusen.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Multi-center, Randomized, Open-label, Phase III Study Comparing PD-1 Inhibitor Combined With Antivascular Therapy and Anthracycline/Taxane-based Adjuvant Chemotherapy Versus Anthracycline/Taxane-based Adjuvant Chemotherapy Alone in Patients With Operable Triple-negative Breast Cancer is being studied. Conditions: TNBC - Triple-Negative Breast Cancer • Eligibility: Inclusion Criteria: 1. Sign the Informed Consent Form (ICF) 2. The patient is judged by the investigator to have the ability to comply with the provisions of the…. Goal: This review will evaluate the efficacy and safety of SHR1210 (Camrelizumab) and antivascular drug(Famitinib) in combination with anthracyclines/taxane-based adjuvant chemotherapy (carrelizumab + FAM + EC-P) compared with conventional chemotherapy regimens (dose-intensive epirubicin and cyclophosphamide, sequential paclitaxel, or EC-P) in patients with early-stage high-risk TNBC. Phase/Status/Sponsor: Unknown phase; RECRUITING; Fudan University.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Circulating Tumor DNA Guided Boost Therapy in Early Triple Negative Breast Patients With Residual Disease After Neoadjuvant Therapy is being studied. Conditions: Breast Cancer • Eligibility: Inclusion Criteria: * Stage II-III breast cancer patients, excluding occult breast cancer, inflammatory breast cancer, metaplasia breast cancer * TNBC patients. TNBC was defined as ER \<= 10%,…. Goal: Early triple negative breast cancer patients who do not achieve pathologic complete response after neoadjuvant chemotherapy with or without immunotherapy have bad prognosis. ctDNA effectively identified patients with highest relapse risk. Phase/Status/Sponsor: Unknown phase; RECRUITING; Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Randomized Secondary Adjuvant Treatment Intervention Study Comparing Trastuzumab-Deruxtecan to SOC Therapy in eBC Patients With Molecular Relapse is being studied. Conditions: Breast Cancer • Eligibility: Inclusion Criteria: Patients will be eligible for study participation if they comply with the following criteria: 1. Written informed consent for all study procedures according to local regulatory…. Goal: Prospective, multi-center, randomized, open label comparative Phase III study in patients with intermediate to high-risk (as defined in the SURVIVE trial) HER2-positive or HER2-low early breast cancer, who participate in the SURVIVE trial and experience a molecular relapse, as assessed based on a positive circulating tumor DNA (ctDNA) result, with 2:1 allocation to: * Arm A: Trastuzumab-Deruxtecan (i.v. 5,4 mg/kg, q3w) + endocrine therapy (if hormonal-receptor-positive) for 16 cycles or until relapse, if earlier * Arm B: Continuous treatment of physician's choice (may include endocrine treatment, CDK4/6-Inhibition, T-DM1, Olaparib, Trastuzumab, Pertuzumab, Capecitabine or Neratinib) Phase/Status/Sponsor: Unknown phase; RECRUITING; Prof. Wolfgang Janni.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

The INTUITT-NF2 Master Study is a basket, multi-arm Phase II trial testing two targeted drugs, brigatinib and neratinib, in people with NF2-related schwannomatosis and progressive NF2 tumors (vestibular schwannomas, non-vestibular schwannomas, meningiomas, and ependymomas). The study aims to learn whether these drugs are safe and can shrink or stabilize tumors by measuring radiographic response rates across tumor types. Eligible participants have an NF2 gene variant or meet NIH/Manchester criteria and show measurable progression of a target NF2-related tumor, and they must be at least 12 years old; key exclusions include recent chemotherapy or radiation to the target tumor, use of other investigational drugs, uncontrolled cardiovascular disease, and pregnancy—note that the brigatinib arm is currently closed to enrollment. About 80 people are planned to participate, with up to 40 per sub-study, and the study can follow participants for up to 10 years, allowing switching between sub-studies if tumors grow.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

The study tests whether adding serplulimab to FLOT chemotherapy improves the rate of complete tumor disappearance (pCR) in adults with stage III gastric adenocarcinoma. It compares serplulimab plus FLOT versus FLOT alone in a randomized design, for patients whose tumors are PD-L1 positive (CPS ≥ 1). Participants receive treatment every two weeks, have imaging at 4 and 8 weeks, then undergo surgery and may receive postoperative serplulimab with adjuvant chemotherapy or adjuvant chemotherapy alone. Key exclusions include HER2-positive tumors, MSI-H/dMMR, autoimmune disease, prior gastric cancer treatment, active infection or pregnancy. Status: ACTIVE_NOT_RECRUITING (the trial is active but not recruiting).

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Omission of Axillary Surgery in Breast Cancer Patients is being studied. Conditions: Breast Cancer, Sentinel Lymph Node, Breast Neoplasms • Eligibility: Inclusion Criteria: * female patients aged \>/=55 years old * unifocal cancer on imaging * breast tumour size based on imaging of \</=3cm * no evidence of axillary…. Goal: The treatment and prognosis of breast cancer (BC) are dependent on its molecular subtype and nodal burden. In early BCs with favourable molecular subtype, the incidence of axillary node involvement is low. Phase/Status/Sponsor: Unknown phase; RECRUITING; KK Women's and Children's Hospital.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

4FMFES-PET Imaging of ER+ Advanced Breast Cancers is being studied. Conditions: ER+ Breast Cancer • Eligibility: Inclusion Criteria: * Advanced breast cancer patients, i.e. stage 3 or 4 diseases. * Aged 18 or older at the time of breast cancer diagnosis. * Histopathologic review…. Goal: Estrogen Receptor (ER) is a crucial prognostic factor and treatment target in breast cancer patients. Knowledge of its status greatly influences the choice of the optimal course of treatment. Phase/Status/Sponsor: Unknown phase; RECRUITING; Centre de recherche du Centre hospitalier universitaire de Sherbrooke.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

The LOGIC trial tests whether adding cryoablation, with or without pembrolizumab, improves immune response and tumor control in high-risk, early-stage triple-negative breast cancer. It will enroll women aged 18 to 90 with clinical stage I/II disease and randomize them to three groups: standard neoadjuvant therapy with surgery, cryoablation followed by neoadjuvant therapy and surgery, or cryoablation plus a single dose of pembrolizumab before cryoablation followed by neoadjuvant therapy and surgery. The study will measure immune and tumor changes in blood and tissue (including TILs, T-cell subsets, and cytokines) at multiple time points. Key exclusions include autoimmune disease or chronic immunosuppression, prior immunotherapy, inflammatory breast cancer, pregnancy or breastfeeding, prior radiation, recent vaccination, and other primary cancers or investigational drug use. Status: NOT_YET_RECRUITING.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Emulation of the MONARCH-3 Trial Using Specialty Oncology Electronic Health Records Databases is being studied. Conditions: Advanced Breast Cancer • Eligibility: Inclusion Criteria: * Female aged ≥18 years at treatment initiation from 2017 - 2023 * Evidence of metastatic breast cancer (MBC) * Documentation of Estrogen/Progesterone receptor-positive (ER/PR+) *…. Goal: Investigators are building an empirical evidence base for real world data through large-scale emulation of randomized controlled trials. The investigators' goal is to understand for what types of clinical questions real world data analyses can be conducted with confidence and how to implement such studies. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; Brigham and Women's Hospital.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Sac-TMT Combined With Toripalimab for First-line Treatment of PD-L1 Positive a/mTNBC is being studied. Conditions: TNBC - Triple-Negative Breast Cancer, PD-L1 Positive • Eligibility: Inclusion Criteria: 1. Female patients with breast cancer aged \>= 18 years. 2. Based on the pathological report of the latest biopsy or other pathological specimens, the histology…. Goal: This study is aimed to evaluate the efficacy and safety of Sacituzumab Tirumotecan combined with Toripalimab for first-line treatment of PD-L1 positive unresectable Locally Advanced/metastatic triple negative breast cancer (a/mTNBC). Phase/Status/Sponsor: Unknown phase; NOT_YET_RECRUITING; Tianjin Medical University Cancer Institute and Hospital.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Combination Chemotherapy With or Without Trastuzumab in Treating Patients With Stage II or Stage III Breast Cancer is being studied. Conditions: Breast Cancer • Eligibility: DISEASE CHARACTERISTICS: * Histologically proven infiltrating ductal or lobular breast carcinoma * Stage II or III disease * Inflammatory breast cancer allowed * Hormone-receptor status not specified PATIENT…. Goal: RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more tumor cells. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; City of Hope Medical Center.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Comparison of the Breast Tumor Microenvironment is being studied. Conditions: Triple Negative Breast Cancer, Hormone Receptor Positive Malignant Neoplasm of Breast • Eligibility: Inclusion Criteria: * Female, age greater than or equal to 40 * Core biopsy proven invasive breast carcinoma or ductal carcinoma in situ (DCIS), all subtypes excluding invasive…. Goal: The goal of the project is to identify a molecular signature of tumor stroma from "normal" adjacent breast tissue obtained prospectively at the time of breast conserving surgery before and after receiving intraoperative radiation therapy (IORT) in subjects that have luminal A and triple negative breast cancer. IORT is considered as being standard of care. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; Columbia University.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

This study tests EGFR-targeted CAR T cell therapy in children and young adults with relapsed or refractory non-CNS solid tumors that express EGFR. It has two arms: Arm A uses EGFR CAR T cells alone, and Arm B adds a CD19-targeting component. It is a phase I, open-label, non-randomized trial to assess safety and feasibility, determine the maximum tolerated dose, describe the toxicity, and see how long the CAR T cells persist and act against tumors. Eligible participants include those with EGFR-expressing non-CNS solid tumors that are recurrent or refractory; early enrollees are ages 15–30, with later enrollees ages 1–30. Key exclusions include active infection, other active cancers, active CNS disease, pregnancy, and GVHD or significant immunosuppression; if severe toxicity occurs, cetuximab or trastuzumab may be used to help eliminate the CAR T cells.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Osimertinib, Cetuximab, and Tucatinib for the Treatment of EGFR-Mutant Stage IV or Recurrent Non-small Lung Cell Cancer is being studied. Conditions: Metastatic Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8 • Eligibility: Inclusion Criteria: * Participants with Stage IV or recurrent/metastatic histologically confirmed non-small cell lung cancer (NSCLC). * NSCLC must harbor at least one of the following EGFR activating…. Goal: This phase I trial tests the safety, side effects, and best dose of osimertinib, cetuximab, and tucatinib in treating patients with EFGR-mutant non-small cell lung cancer that is stage IV or has come back (recurrent). Osimertinib and tucatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Phase/Status/Sponsor: Unknown phase; NOT_YET_RECRUITING; Jonathan Riess.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

- The study tests molecular analyses of blood, tumor tissue, normal tissue, and other body fluids to learn about cancer development, growth, and spread. - It is for adults with thoracic cancers: non-small cell lung cancer, small cell lung cancer, thymoma, thymic carcinoma, mesothelioma, or cancer of unknown primary presenting in the chest. - The goal is to identify markers that help diagnose cancer, predict outcomes, and predict response to targeted therapies, and to find targets for new treatments. - The project aims to create a registry of patients and tumors to better understand molecular changes in thoracic cancers and aid early detection. - Enrollment is by invitation, and participants must be able to give informed consent.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Testing AZD5363 as a Potential Targeted Treatment in Cancers With AKT Genetic Changes (MATCH-Subprotocol Y) is being studied. Conditions: Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Hematopoietic and Lymphoid Cell Neoplasm +3 • Eligibility: Inclusion Criteria: * Patients must have met applicable eligibility criteria in the Master MATCH Protocol prior to registration to treatment subprotocol * Patients must have an AKT mutation…. Goal: This phase II MATCH treatment trial identifies the effects of AZD5363 in patients whose cancer has a genetic change called AKT mutation. AZD5363 may block AKT, which is a protein needed for cancer cell growth. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; National Cancer Institute (NCI).

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Testing Copanlisib as Potentially Targeting Treatment in Cancers With PTEN Loss (MATCH - Subprotocol Z1G) is being studied. Conditions: Malignant Solid Neoplasm • Eligibility: Inclusion Criteria: * Patients must have met applicable eligibility criteria in the Master MATCH Protocol EAY131/ NCI-2015-00054 prior to registration to treatment subprotocol * Patients must fulfill all…. Goal: The phase II MATCH treatment trial tests how well copanlisib works to treat patients with cancer with PTEN loss. Copanlisib may stop the growth of tumor cells and may kill them by blocking some of the enzymes needed for cell growth. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; National Cancer Institute (NCI).

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

LYNPARZA Breast Cancer in the Adjuvant Setting Japan Post-Marketing Surveillance (PMS) is being studied. Conditions: Breast Cancer • Eligibility: Inclusion Criteria: * The patients who started treatment with LYNPARZA for the first time for the approved indication "Adjuvant treatment for patients with BRCA-mutated HER2 negative high recurrent…. Goal: To evaluate the frequency of bone marrow suppression Adverse Drug Reactions (ADRs) in patients with BRCA mutated HER2 negative high recurrent risk breast cancer treated with LYNPARZA for adjuvant treatment in the actual post-marketing use. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; AstraZeneca.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Phase 2 Study of Cediranib in Combination With Olaparib in Advanced Solid Tumors is being studied. Conditions: Advanced Malignant Solid Neoplasm, Metastatic Lung Non-Small Cell Carcinoma, Metastatic Lung Small Cell Carcinoma +23 • Eligibility: Inclusion Criteria: * Patients must have histologically confirmed, metastatic or unresectable malignancy of the following types: (a) non-small cell lung cancer (NSCLC), (b) triple-negative breast cancer (TNBC; defined…. Goal: This phase II trial studies cediranib maleate in combination with olaparib in treating patients with solid tumors that have spread to other parts of the body (advanced/metastatic) or cannot be removed by surgery (unresectable), including breast cancer, non-small cell lung cancer, small cell lung cancer, and pancreatic cancer. Cediranib maleate and olaparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; National Cancer Institute (NCI).

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

[18F]FLT PET/CT in Rb+ Metastatic Breast Cancer is being studied. Conditions: Breast Neoplasm, Metastatic Breast Cancer, Rb+ Breast Cancer • Eligibility: Inclusion Criteria: 1. At least 18 years of age 2. History of histologically or cytologically confirmed breast cancer, any ER, PR or HER2 status is allowed as long…. Goal: In this study positron emission tomography (PET/CT) imaging will be used to evaluate proliferative activity in sites of metastatic disease using the investigational radiotracer \[18F\]fluorothymidine (FLT). Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; University of Pennsylvania.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Prospective Multicenter Single-arm Trial: AK112 + Nab-paclitaxel/Carboplatin Neoadjuvant for TNBC is being studied. Conditions: Breast Cancer - Female • Eligibility: Inclusion Criteria: 1. Voluntary Participation and Informed Consent: The participant voluntarily agrees to join this clinical trial, signs a written informed consent form, understands the study, and is…. Goal: This prospective, multicenter, single-arm clinical study aims to evaluate the efficacy and safety of AK112 in combination with albumin-bound paclitaxel and carboplatin as neoadjuvant treatment in adult women with early or locally advanced triple-negative breast cancer (TNBC). The study seeks to address the pathological complete response (pCR) rate, objective response rate (ORR), breast conservation rate, and invasive disease-free survival (iDFS) following treatment with AK112 combined with albumin-bound paclitaxel and carboplatin in early or locally advanced TNBC. Phase/Status/Sponsor: Unknown phase; NOT_YET_RECRUITING; Shuangyue Liu.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

C7R-GD2.CART Cells for Patients With Relapsed or Refractory Neuroblastoma and Other GD2 Positive Cancers (GAIL-N) is being studied. Conditions: Relapsed Neuroblastoma, Refractory Neuroblastoma, Relapsed Osteosarcoma +4 • Eligibility: Procurement Inclusion Criteria: 1. Evaluable neuroblastoma with persistent or relapsed disease 1. Recurrent disease following completion of aggressive multi-drug frontline therapy. 2. Progressive disease during aggressive multi-drug frontline…. Goal: This study is for patients with neuroblastoma, sarcoma, uveal melanoma, breast cancer, or another cancer that expresses a substance on the cancer cells called GD2. The cancer has either come back after treatment or did not respond to treatment. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; Baylor College of Medicine.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Personalized Vaccine for TNBC Immunotherapy is being studied. Conditions: Breast Cancer Female • Eligibility: Inclusion Criteria: 1. Be between 18 and 75 years of age. 2. Histologically confirmed diagnosis of primary triple negative breast carcinoma (TNBC). 3. Patients who have already been…. Goal: Due to their genetic instability, breast tumors that do not express receptors for Estrogens, Progestagens or amplify the Her2 / neu oncogene \[called triple-negative breast cancer (TNBC)\] and other tumors such as melanoma, non-small cell lung cancer, accumulate numerous mutations that make them highly resistant to different regimens of chemo- or radiotherapy, thereby generating high morbidity and mortality. However, immunology can turn the genetic instability of tumors into the Achilles' tendon. Phase/Status/Sponsor: Unknown phase; NOT_YET_RECRUITING; Universidad Nacional de Colombia.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Study Assessing the Efficacy and Safety of Treatment With Alpelisib Plus Fulvestrant Versus Placebo Plus Fulvestrant in Chinese Men and Postmenopausal Women With Advanced Breast Cancer is being studied. Conditions: Breast Neoplasms • Eligibility: Key Inclusion Criteria: * Participant has adequate tumor tissue for the analysis of PIK3CA mutational status by a Novartis designated laboratory. One new or recent biopsy (collected at…. Goal: The primary objective is to evaluate whether treatment with alpelisib in combination with fulvestrant prolongs Progression Free Survival (PFS) compared to treatment with placebo in combination with fulvestrant. The primary scientific question of interest is: what is the treatment effect based on PFS for alpelisib in combination with fulvestrant versus placebo in combination with fulvestrant in Chinese men and postmenopausal women with HR-positive, HER2-negative advanced breast cancer with a PIK3CA mutation, who received prior treatment with an aromatase inhibitor (AI) either as (neo) adjuvant treatment or as treatment for advanced disease, regardless of study treatment discontinuation or start of new anti-neoplastic therapy. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; Novartis Pharmaceuticals.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

CFI-400945 and Durvalumab in Patients With Advanced Triple Negative Breast Cancer is being studied. Conditions: Breast Cancer • Eligibility: Inclusion Criteria: * Patients must have histologically and/or cytologically confirmed diagnosis of breast cancer, that is advanced/metastatic or unresectable, for which no curative therapy exists, and be negative…. Goal: The purpose of this study is to find out the effect that CFI-400945 and durvalumab have on breast cancer. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; Canadian Cancer Trials Group.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

The Role of Mucosal Associated Invariant t Lymphocytes in Breast Cancer is being studied. Conditions: Breast Cancer • Eligibility: Inclusion Criteria: * Female patients admitted at South Egypt cancer institute who diagnosed as breast cancer based on full clinical, radiologic and pathologic assays Exclusion Criteria: 1. Patients…. Goal: Evaluation of MAIT cells in patient recently diagnosed as cancer breast and its correlation with clinical outcome. Mucosal Associated Invariant T cells are a population of unconventional T cells which are enriched in mucosal tissues such as the lung and gut but are also present in other tissues including the skin, adipose tissue and the liver \[4,5,6,7\]. Phase/Status/Sponsor: Unknown phase; NOT_YET_RECRUITING; Assiut University.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Phase III Trial of Camrelizumab+Apatinib+Eribulin vs. Physician's Choice Chemotherapy in Advanced Triple-Negative Breast Cancer is being studied. Conditions: Breast Cancer Stage IV • Eligibility: Inclusion Criteria: 1. The subject voluntarily agrees to participate in this study and signs an informed consent form (ICF). 2. Female subjects aged ≥18 and ≤70 years on…. Goal: This study evaluates the efficacy and safety of camrelizumab, apatinib, and eribulin versus physician's choice chemotherapy in advanced TNBC.Primary Objectives: Assess improvements in progression-free survival (PFS) and overall survival (OS).Secondary Objectives: Compare objective response rate (ORR), disease control rate (DCR), clinical benefit rate (CBR), duration of response (DoR), time to response (TTR), two-year OS rate, biomarker analysis, and quality of life (QoL).Safety: Assess and compare adverse event incidence and severity. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Study of JK08 in Patients with Unresectable Locally Advanced or Metastatic Cancer is being studied. Conditions: Cancer, Tumor, Solid, Advanced Solid Tumor +19 • Eligibility: Inclusion Criteria: 1. Age ≥ 18 years old. 2. Signed informed consent and willing and able to comply with study procedures and scheduled visits. 3. For Dose Escalation,…. Goal: This is a Phase 1/2, open-label, multi-center, first-in-human, dose escalation and cohort expansion study evaluating multiple doses and schedules of subcutaneously administered JK08 in patients with unresectable locally, advanced or metastatic cancer. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; Salubris Biotherapeutics Inc.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Phase 1 Study of [225Ac]-FPI-1434 Injection is being studied. Conditions: Advanced Solid Tumours, Endometrial Cancer, Cervical Cancer +7 • Eligibility: Inclusion Criteria: 1. Pathologically documented, definitively diagnosed, advanced solid tumour that is refractory to all standard treatment, for which no standard treatment is available, or it is contraindicated,…. Goal: This is a first-in-human Phase 1/2, non-randomized, multi-centre, open-label clinical study designed to investigate safety, tolerability, PK, and preliminary anti-tumour activity of \[225Ac\]-FPI-1434 (radioimmuno-therapeutic agent) in patients with solid tumours that demonstrate uptake of \[111In\]-FPI-1547 (radioimmuno-imaging agent), and to establish the maximum tolerated dose (MTD) and/or the recommended Phase 2 dose (RP2D) of repeat doses of \[225Ac\]-FPI-1434 Injection in patients with solid tumours that demonstrate uptake of \[111In\]-FPI-1547 (radioimmuno-imaging agent). Phase/Status/Sponsor: Unknown phase; TERMINATED; Fusion Pharmaceuticals Inc..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Study of DS-8201a in Subjects With Advanced Solid Malignant Tumors is being studied. Conditions: Advanced Solid Tumors • Eligibility: Inclusion Criteria: * Eastern Cooperative Oncology Group performance status( PS) of 0 or 1. * Left Ventricular Ejection Fraction (LVEF) ≥ 50% Part 1: * Advanced/unresectable or metastatic…. Goal: This is an open-label, two-part, multicenter study to evaluate the safety and tolerability of DS-8201a in participants with advanced solid malignant tumors. Phase/Status/Sponsor: Unknown phase; COMPLETED; Daiichi Sankyo Co., Ltd..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Breast Cancer Study of Stereotactic Body Radiation Therapy (SBRT) Combined Neoadjuvant Treatment is being studied. Conditions: Breast Cancer • Eligibility: Inclusion Criteria: * Confirmed histologic diagnosis of invasive adenocarcinoma of the breast * ER, PR and HER2 testing, and * TNBC patients （ HER2-neu 0-1+ by IHC or…. Goal: The study is being conducted to evaluate the efficacy and safety of stereotactic body radiation therapy (SBRT) combined neoadjuvant treatment for patients with triple-negative and hormone receptor-positive, HER2-negative breast cancer Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; Shengjing Hospital.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Neoadjuvant Nivolumab and Chemotherapy in Patients With Localized Triple-negative Breast Cancer is being studied. Conditions: Triple Negative Breast Cancer • Eligibility: Inclusion Criteria: * Histologically or cytologically confirmed newly diagnosed ER-/HER2- breast cancer. ER and PR \< Allred score of 3 or \< 1% positive staining cells in the…. Goal: Prior to Amendment #7: The hypothesis of this study is that the combination of cabiralizumab and nivolumab with neoadjuvant chemotherapy will decrease tumor associated macrophages (TAMs) and increase tumor infiltrating lymphocytes (TIL) compared to neoadjuvant chemotherapy plus nivolumab in patients with early stage triple-negative breast cancer (TNBC) and improve clinical outcomes. As of Amendment #7 IRB approved 10/13/2022: The study will no longer enroll to Arm B. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; Washington University School of Medicine.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Health Care Coach Support in Reducing Acute Care Use and Cost in Patients With Cancer is being studied. Conditions: Acute Myeloid Leukemia, Brain Glioblastoma, Estrogen Receptor Negative +64 • Eligibility: Inclusion Criteria: * Newly diagnosed patients for the following conditions * Colon cancer stage III and IV * Rectal cancer stage II, III, IV * Glioblastoma multiforme (brain)…. Goal: This randomized pilot clinical trial studies health care coach support in reducing acute care use and cost in patients with cancer. Health care coach support may help cancer patients to make decisions about their care that matches what is important to them with symptom management. Phase/Status/Sponsor: Unknown phase; COMPLETED; Stanford University.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

1st Line Treatment of Bevacizumab-Taxane vs Bevacizumab-Exemestane in Metastatic Breast Cancer is being studied. Conditions: First Line Metastatic Breast Cancer • Eligibility: Inclusion Criteria: * Age \> 18 ans. * Metastatic breast cancer or locally advanced * RE+, HER2- * Patient receiving paclitaxel-bevacizumab first line chemotherapy Exclusion Criteria: * Previous…. Goal: In first-line metastatic breast cancer, the bevacizumab-taxane to progression or toxicity, is currently the standard treatment. In patients expressing hormone receptors, it was shown that hormone therapy administered in maintenance after induction chemotherapy, could have a benefit regarding the progression-free survival. Phase/Status/Sponsor: Unknown phase; TERMINATED; ARCAGY/ GINECO GROUP.

This summary may be inaccurate. Verify against ClinicalTrials.gov.